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Abstract 
 
Retroviruses possess an RNA genome that is reverse transcribed into DNA and 
becomes integrated into the host genome during infection. Human immunodeficiency 
virus 1 (HIV-1) belongs to the genus lentivirus of the retroviridae family and is a major 
human pathogen with more than 50 million infected people worldwide to date. 
Lentiviruses have very narrow host ranges. Cross-species lentiviral transmissions are 
rare, due to the ability of mammals to counteract viral infections by the innate immune 
system, which includes intracellular factors that block virus replication. Of these, the 
murine protein Fv1 and the tripartite (RBCC) motif protein family member TRIM5α 
potently inhibit retroviral infections early after virus cell entry. 
This study presents evidence that antiviral activity exerted by TRIM5α is conserved 
across mammals. Rabbit cells are strongly non-permissive to infections by certain 
retroviruses including HIV-1. The study identifies a TRIM5α orthologue in rabbits, 
which possesses antiretroviral activity. Phylogenetic analysis demonstrates that rabbit 
TRIM5 is a true orthologue and clusters with other mammalian TRIM5 genes.  
Remarkably, TRIM5 fusion proteins with the prolyl-peptidyl isomerase cyclophilin A 
(CypA) have independently evolved twice by retrotransposition of a CypA cDNA into 
the TRIM5 genomic locus, generating a viral restriction factor with a CypA binding 
domain. This study shows that CypA fusion proteins with RBCC domains of other 
TRIM proteins also function as restriction factors against HIV-1. Furthermore, fusion of 
CypA to Fv1 enables the restriction of HIV-1 and FIV. Insights into the mechanism of 
TRIM5α restriction are also provided in this study. Functional analyses of TRIM5α and 
TRIMCyp deletion mutants, as well as fusion proteins of Fv1Cyp with the TRIM5α 
RING and B-box domains, indicate that the RING and B-box domains mediate the 
proteasome dependent block to reverse transcription during TRIM5α/TRIMCyp 
restriction. The results suggest that the major antiviral activity exerted by TRIM5α is a 
RING dependent block to reverse transcription, whereas the major activity of TRIMCyp 
is independent of RING function. 
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1. Introduction 
1.1. HIV-1 is the prototypic lentivirus 
Human immunodeficiency virus 1 (HIV-1), the etiologic cause of the acquired 
immunodeficiency syndrome (AIDS), was first isolated in 1983 from the lymph node of 
a person with lymphadenopathy by Francoise Barré-Sinoussi, Jean-Claude Chermann 
and Luc Montagnier at the Institute Pasteur in Paris [1]. However, the identified isolate, 
called Bru, replicated poorly in cell culture and was, unrecognised by researchers at the 
Institute Pasteur, contaminated by a more robustly and quickly replicating second AIDS 
isolate, called Lai. Samples labelled as Bru but contaminated with Lai were sent to other 
labs including the lab of Robert Gallo at the U.S. National Institute of Health. Almost 
one year after the original discovery of Bru, the Gallo lab reported the isolation of a T-
cell tropic retrovirus robustly replicating in cell culture, named human T-cell 
lymphotropic virus type III (HTLV-III), which subsequently was identified to be similar 
to the isolate Lai [2]. The lab around Simon Wain-Hobson reconstructed the chain of 
events [3] and Barré-Sinoussi and Montagnier obtained the Nobel Prize for Medicine 
for their discovery in 2008. Early names for the discovered virus were LAV, 
lymphadenopathy-associated virus (Institute Pasteur Paris); HTLV-III (U.S. NIH) and 
ARV, AIDS-associated retrovirus (University of California, San Francisco), but in 1986 
the name human immunodeficiency virus was assigned due to the virus’s relatedness 
with a group of known lentiviruses. Three years after the discovery of HIV, a second 
distantly related human immunodeficiency virus (HIV-2) was discovered in a distinct 
region in West Africa, which also caused AIDS in humans, however in fewer numbers 
of infected people compared to HIV-1 [4].  
One of the oldest known lentiviruses is equine infectious anaemia virus, EIAV, which 
causes an autoimmune haemolytic anaemia in horses (Table 1) and was found in 1904 
as a filterable agent causing anaemia in horses [5] although its relatedness to HIV-1 was 
only discovered in 1986 [6]. After the discovery of HIV, scientists identified a similar 
lentivirus in cats (FIV, feline immunodeficiency virus formerly known as feline T-
lymphotropic virus) [7] and in diverse non-human primates (SIV, simian 
immunodeficiency virus) [8-11]. 
Due to its impact on human health, HIV-1 is the most exhaustively studied lentivirus to 
date but still is only partially understood.  
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1.2. The origin of HIV-1  
HIV-1 originates from a simian immunodeficiency virus infecting chimpanzees (Pan 
troglodytes troglodytes) designated SIVcpzPtt, which is thought to have crossed species 
three times resulting in the emergence of HIV-1 virus group M, which caused the AIDS 
pandemic and HIV-1 group N, which is geographically restricted to a region of 
Cameroon (FIG 1) [12, 13]. In addition, recent data suggests that SIVcpzPtt may also be 
the origin of HIV-1 group O (FIG 1) [14]. SIVcpzPtt is also thought to have crossed 
species infecting western low land gorillas (Gorilla gorilla gorilla), leading to the 
emergence of SIVgor [14, 15]. In contrast, HIV-2 is most closely related to SIVsm (FIG 
1), indicating that HIV-2 infection in humans was a result of a zoonotic transmission of 
SIVsm from sooty mangabeys to humans [16]. Interestingly, the earliest lymph node 
biopsies, both derived from Léopoldville (today Kinshasa, Democratic Republic of the 
Congo), in which HIV-1 group M virus could be detected, date from 1959 and 1960 
[17, 18]. The divergence of the two isolated sequences (12 % sequence difference) 
points to a much earlier date of zoonotic transmission of SIVcpzPtt from chimpanzees 
to human, suggesting that HIV-1 may have been circulating long before 1960.  
Lentiviruses have narrow host ranges and HIV-1 only replicates in humans, 
chimpanzees [19] and possibly gorillas [15]. Interestingly, early studies suggested that 
HIV-1 infection of chimpanzees almost always appears non-symptomatic and only one 
HIV-1 infected chimpanzee from the Yerkes cohort showed progression of HIV-1 
infection to AIDS [20, 21]. However, recent reports increasingly suggest that infection 
of chimpanzee with SIVcpzPtt, the closest relative of HIV-1, leads to a symptomatic 
infection and can progress to AIDS [22]. SIVcpzPtt can be transmitted horizontally 
between chimpanzees and infections increase the risk for mortality by 15-fold [22]. 
Moreover, significantly more chimpanzee babies born to SIVcpzPtt infected mothers 
die compared to infants born to uninfected mothers, suggesting mother to child 
transmission of SIVcpzPtt [22].  
Although this may provide a new approach for an animal model, chimpanzees as well as 
gorillas are endangered, experiments are cumbersome and expensive and therefore these 
animals do not present a suitable model for HIV-1/AIDS research. Many attempts have 
been undertaken to find a small animal model. Gibbons (Hylobates lar) and pigtailed 
macaques (Macacca nemestrina) have been infected with HIV-1 and studied as possible 
animal models for infection [23, 24]. However, the replication of HIV-1 remained poor, 
and in all cases infections were non-pathogenic and did not lead to AIDS. In the 1970’s 
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before HIV was discovered, experiments studying the disease Kuru led to the 
transmission of an SIV from sooty mangabeys (sm) to rhesus macaques (mac) and the 
emergence of two viruses (SIVstm and SIVmac) that caused AIDS in sooty mangabeys 
as well as in rhesus macaques (Table 1) [25]. In addition, SIVsm and SIVmac infection 
of cynomolgus macaques causes AIDS, and these systems are studied as surrogate 
models for human AIDS [26-28].  
Furthermore, SIV-HIV-1 chimaeric virus infection of macaques has been studied as a 
model for HIV-1 infection. This system was used for attempts to develop an attenuated 
live vaccine, and has been proven useful to test reverse transcriptase inhibitors in vivo 
[29, 30]. Early studies of infection of pigtailed macaques (Macacca nemestrina) with 
HIV-1 showed that they were partially permissive for HIV-1 replication as well as 
replication of HIV(NL-DT5R), a chimaeric mutant in which 7 amino acids of CA and 
the entire vif gene were replaced by SIV sequences [23, 31-33]. More recently, pigtailed 
macaques were infected with a SIV-HIV-1 chimaera in which only the HIV-1 vif gene 
was replaced by SIVmac or HIV-2 vif  [34]. The study showed that the chimaeric virus 
(stHIV-1) was able to cause acute viremia in infected animals similar to viremia levels 
seen in HIV-1 infected humans and that virus replication was persistent over several 
months but was eventually controlled at least partially by CD8+ T-cell activity [34]. In 
contrast to most Old World monkeys, which express a TRIM5α that blocks HIV-1 
infection, pigtailed macaques express a TRIM5-cyclophilin A fusion protein that is 
unable to restrict HIV-1 infectivity and may counteract endogenous TRIM5α [35]. 
Furthermore, a study infecting cynomolgus and rhesus macaques with SIV-HIV-2 Env 
or Gag/Pol chimaeric viruses demonstrated that virus could be recovered from rhesus 
macaques up to twelve weeks after challenge, indicating persistence of the chimaeras in 
these animals [36].  
In addition to primate animal models, FIV infection of cats has been proposed as a 
surrogate model for HIV-1 infection in humans [37-41]. Cats are suitable since after 
infection with FIV they develop AIDS like symptoms including a self-limiting acute 
disease, followed by an asymptomatic phase with loss of CD4 and CD8 T-cells and pre-
AIDS disorders (Table 1) [37, 42]. Therefore they are currently used to test different 
vaccine strategies against FIV, which may reveal novel ways for HIV-1 vaccine 
development.   
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Virus Host Species Disease 
HIV-1 Human immunodeficiency virus 1 Human AIDS 
HIV-2 Human immunodeficiency virus 2 Human AIDS 
SIVmac Simian immunodeficiency virus Macaques AIDS 
SIVcpzPtt Simian immunodeficiency virus Chimpanzees (AIDS?) 
SIVgor Simian immunodeficiency virus Gorillas unknown 
SIVsm Simian immunodeficiency virus Sooty mangabeys unknown 
SIVrcm Simian immunodeficiency virus Red capped mangabeys unknown 
SIVagmTan Simian immunodeficiency virus Tantalus monkeys unknown 
SIVagmSab Simian immunodeficiency virus Vervet monkeys unknown 
FIV Feline immunodeficiency virus Cats AIDS 
EIAV Equine infectious anaemia virus Horses Anaemia 
MLV Murine leukaemia virus  Mice Cancer 
Table 1 Retroviruses, host species and disease caused in the host  
Depicted are retroviruses, the hosts in which these viruses are found and the diseases the viruses cause in 
its hosts. Gag expression vectors from grey highlighted viruses have been analysed in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 1 Phylogenetic tree of lentiviruses 
Depicted is the phylogenetic relationship between lentiviruses. Gag expression vectors from bold viruses 
were analysed in this study. RELIK, rabbit endogenous lentivirus; EIAV, equine infectious anaemia 
virus; BIV, bovine immunodeficiency virus; FIV, feline immunodeficiency virus; SIV, simian 
immunodeficiency virus; HIV, human immunodeficiency virus; agm, African green monkey. Scale 
indicates substitutions per site. Figure adapted from [43]. 
Ovine-caprine lentiviruses (e.g. Visna) 
Bovine lentiviruses (e.g. BIV) 
Feline lentiviruses (e.g. FIV) 
SIVgml (from gray mouse lemur, extinct) 
SIVagmTan (from Tantalus monkeys) 
HIV-1 O-group  
HIV-1 N-group 
HIV-1 M-group 
SIVcpz (from chimpanzees) 
SIVrcm (from red capped mangabeys) 
HIV-2 
SIVagmSab (from vervet monkeys) 
SIVsm (from sooty mangabeys) 
SIVmac (from macaques) 
Equine lentiviruses (e.g. EIAV) 
RELIK (from rabbits and hares, extinct) 
0.25 
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1.3. Genomic organisation of HIV-1 
The HIV-1 genome is diploid consisting of two RNA molecules of positive polarity 
each of approximately 9 kb in length. Like cellular mRNAs both viral RNA molecules 
are 5’ capped with 7-methylguanosine and possess a 3’ polyA tail [44]. The genomic 
RNAs are packaged into nascent HIV-1 particles and are the template for reverse 
transcription in an infected cell, generating viral DNA that is integrated into the host 
genome establishing a provirus. The synthesis of the two full-length genomic RNAs is 
mediated from the provirus via a promoter region in the 5’ long terminal repeat (LTR) 
region (FIG 2).  Viral genomic RNAs contain cis-acting elements like the trans-
activating responsive region (TAR), the Rev responsive element (RRE), the primer 
binding site (PBS), the packaging signal Ψ and the 3’ and central polypurine tracts 
(PPT), that are essential for diverse steps in the virus life cycle. HIV-1 encodes the 
typical retrovirus polypeptides Gag (group-specific antigen), Pol (polymerase) and Env 
(envelope) as well as additional proteins Vif, Vpr, Vpu, Nef, Tat and Rev. All the 
proteins are expressed from different splice forms of a single RNA transcript and are 
important for a natural occurring infection.  
 
FIG 2 Genetic organisation of HIV-1  
HIV-1 consists of the polyproteins Gag, Pol and Env and has additional auxiliary proteins Vif (viral 
infectivity factor), Vpr (viral protein R), Vpu (viral protein unique), Rev (regulator of virion expression), 
Tat (transactivator of transcription) and Nef (negative factor). The 55kDa Gag polyprotein consists of the 
proteins MA (matrix), CA (capsid), the spacer protein p2, NC (nucleocapsid), spacer peptide p1 and the 
p6 protein. Cleavage of Gag into the individual proteins occurs after virus assembly in a process referred 
to as maturation. Pol is synthesised as a 160kDa Gag-Pol protein and encodes the viral protease (PR), the 
reverse transcriptase (RT), which is expressed as two different subunits p51 and p66 building a functional 
dimer, and the integrase (IN). The Env protein has an N-terminal signal peptide sequence, and is cleaved 
into gp120, the surface protein (SU), and gp41, the transmembrane protein (TM), both proteins being 
involved in attachment to cellular receptor/ co-receptor complexes and membrane fusion of viral and 
cellular membrane. Viral cis acting elements include the two long terminal repeats (LTR’s), the primer 
binding site (PBS), the TAR stem loop that is bound by Tat for transcription activation, the Rev 
responsive element (RRE) which is bound by Rev mediating nuclear export of partially spliced and 
unspliced RNAs, a 3’ and a central polypurine tract (PPT) and the RNA packaging signal Ψ. Figure 
adapted from [45]. 
cPPT 3‘PPT 
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1.4. The HIV-1 life cycle 
The HIV-1 life cycle comprises several steps including the attachment of the virus to the 
cell, the release of its capsid into the cytoplasm, reverse transcription of the viral RNA 
into DNA, trafficking and nuclear import of pre-integration complexes, integration of 
the DNA into the host genome establishing the provirus, transcription and nuclear 
export of mRNAs as well as genomic RNAs, synthesis of viral proteins and virus 
assembly at the plasma membrane, and a final step of maturation to generate infectious 
progeny virions (FIG 3). 
Uncoating
Reverse transcription
Integration
Transcription
Translation
Nuclear 
Import
Packaging
Assembly
Maturation
Attachment
Entry
Receptor/Co-receptor
CD4/CXCR4
CD4/CCR5
Viral proteins
Tat, Rev, Nef, Vif, Vpu, Vpr
Gag, GagPol, Env
Rev, Tat
Provirus
2-LTR 
circles
Rev independent: 
Tat, Rev, Nef mRNAs
Tat activated 
transcription
1-LTR 
circles
ESCRT machinery
Protease cleavage
Nuclear 
Export
 
FIG 3 Life cycle of HIV-1 
HIV-1 entry is initiated by the attachment of the gp120 envelope protein to the CD4 receptor and 
subsequent interaction with the co-receptors of the family of chemokine receptors. Fusion of host and 
virus membrane occurs with help of the fusion peptide in gp41. After membrane fusion the capsid is 
released into the cytoplasm where it undergoes a poorly understood process referred to as uncoating 
before the viral genome consisting of two single stranded RNAs of positive polarity is copied into one 
strand of double stranded DNA by the enzyme reverse transcriptase. The viral DNA is transported into 
the nucleus where it is integrated into the host genome by the viral enzyme integrase. In addition, two 
forms of circularised viral DNA are found, 1-LTR and 2-LTR circles. Proviral transcripts encoding for 
Rev and Tat are spliced, mRNAs are exported and synthesised Rev and Tat proteins are transported into 
the nucleus where they ensure efficient viral transcription (Tat) and the export of partially spliced mRNAs 
and genomic RNAs (Rev). Exported viral mRNAs are translated into Gag, GagPol and Env proteins and 
full-length viral genome RNA is packaged into virions. Assembly and budding of new virus is mediated 
by the host ESCRT-I/II/III machineries at the plasma membrane. After virus release, HIV-1 undergoes a 
maturation process during which Gag is cleaved and the cone shaped capsid shell is formed. 
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1.4.1. Attachment of HIV-1 and cell entry 
The first step in the life cycle of HIV-1 is its attachment to the cell (FIG 3). HIV-1 
infects CD4+ T-cells as well as macrophages using CD4 as a receptor [46]. CD4 is an 
integral membrane protein of the Ig superfamily and contains four Ig-like domains. CD4 
associates with the T-cell receptor (TCR) and participates in signal transduction after 
recognition of MHC class II bound antigens by the TCR. The involvement of CD4 in 
the life cycle of HIV-1 was first observed when CD4+ Jurkat T-cells formed giant 
multinucleated syncytia in response to the glycoproteins of HIV-1 [46, 47]. The 
existence of at least one co-receptor for HIV-1 was considered by the observation that 
mouse cells did not become susceptible for HIV-1 after expression of human CD4. The 
co-receptors CXCR-4 and CCR5 were only discovered in 1996 [48, 49]. Depending on 
the co-receptor usage one can distinguish between CCR5 tropic and CXCR-4 tropic 
viruses as well as viruses that have a dual tropism. During the early stage of HIV-1 
infection predominantly virus using CCR5 is found, whereas CXCR-4 tropic viruses 
occasionally arise at a later stage during the progression towards AIDS [50]. CXCR-4 
and CCR5 are integral membrane proteins and belong to the class of chemokine 
receptors that bind the chemokines SDF-1 (CXCR-4) and RANTES, MIP-1α and 
MIP-1β (CCR5), respectively [51]. In addition, the chemokine receptor CCR3 has been 
suggested as another co-receptor for HIV-1 [52].  
Interestingly, some people are partially resistant to infection by HIV-1 due to a 
homozygous 32 bp deletion in the coding region of their CCR5 genes leading to a 
truncated, non-functional receptor [53, 54]. This mutated CCR5 allele not only prevents 
infection in people that are homozygous for the deletion. People that are heterozygous 
for CCR5d32 seem to have a slower CD4+ T-cell decline and progress more slowly to 
AIDS [55-57]. The identification of the co-receptors for HIV-1 entry has led to the 
development of antagonising drugs, e.g. Maraviroc for CCR5, which has recently 
passed clinical trial phase III [58]. However, mutants resistant to Maraviroc have been 
reported and were mapped to the variable loop 3 (V3) of gp120 as well as to the fusion 
peptide of gp41 [59]. CXCR-4 antagonists have also recently been developed and new 
drugs are under clinical evaluation [60, 61]. However, CXCR-4 antagonists like 
AMD3100 may be less suitable than CCR5 antagonists since several side effects on 
normal cell functions have been observed [62].  
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HIV-1 binding to the cellular receptor/ co-receptor complex is mediated through its 
envelope glycoproteins gp120 and gp41, which are derived from a gp160 precursor 
protein that is cleaved in virus producing cells by the cellular peptidase furin and other 
proteases [63]. Gp160 is synthesised in the rough endoplasmic reticulum where it gets 
heavily glycosylated at asparagine residues. The protein then undergoes modification in 
the Golgi in which the mannose glycosylation is further processed and the surface (SU/ 
gp120) and transmembrane (TM/ gp41) proteins are generated by endoproteolytic 
cleavage, an event that is essential for the generation of infectious virions [64]. Both 
proteins remain non-covalently attached and are transported to the plasma membrane 
where they form trimers, also referred to as spikes. Each newly formed virion 
incorporates approximately 8-10 trimers of gp120/gp41 [65]. Mutations that affect the 
cleavage of the gp160 precursor or that affect the association of the gp120 and gp41 
subunits render HIV-1 non-infectious [66]. Gp120 and gp41 have distinct functions in 
virus attachment to the cell and fusion of the virus membrane with the host cell 
membrane. As an initial step gp120 binds to CD4 (FIG 4A). After gp120 binding to 
CD4, a binding site in gp120 is exposed, which attaches to the co-receptor (FIG 4B). 
Binding to the co-receptor leads to a conformational change in gp41 so that the formerly 
unexposed fusion peptide becomes exposed. This fusion peptide inserts into the target 
cell membrane and mediates membrane fusion. In a process similar to structural 
changes seen for SNARE proteins involved in membrane fusion of vesicles, the two 
alpha helices (HR1 and HR2) of a gp41 monomer form a rod-like hairpin structure 
thereby bringing viral and cellular membranes closer together so that fusion can occur 
(FIG 4C). The resulting post-fusion structure of gp41, a six-helix bundle, is depicted in 
FIG 5. The events occurring at this stage are also strikingly similar to events happening 
during influenza HA mediated membrane fusion however, unlike for HA they are not 
dependent on a low pH. Recent data however suggests that the fusion of viral and host 
cell membranes occurs in endosomes and not directly at the plasma membrane [67]. 
Fusion of the viral and cellular membrane leads to the release of the virus capsid shell 
into the cytoplasm.  
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FIG 4 Attachment of HIV-1 and events occurring during membrane fusion  
A) HIV-1 attaches to cell membrane associated CD4 via the gp120 protein.  B) Attachment brings the 
virus closer to the cell membrane and induces a conformational change in the gp120 protein so that it can 
bind to the co-receptor C) Binding to the co-receptor leads to the exposure of the gp41 fusion peptide 
which inserts into the host cell membrane. Formation of a helix bundle leads to annealing of virus and cell 
membranes causing membrane fusion. Fusion is thought to occur after endocytosis. Figure adapted from 
[68].   
 
 
 
 
FIG 5 Six-helix bundle gp41 post fusion structure  
HIV-1 glycoprotein 41 (gp41) contains an N-terminal fusion peptide that is inserted into the target cell 
plasma membrane. Each monomer of gp41 has two helical domains (HR1 and HR2), which form helical 
bundles during membrane fusion. In the fused membrane, gp41 is found as a trimeric structure in a six-
helix bundle. Figure adapted from [69]. 
 
 
1.4.2. Reverse transcription of HIV-1  
During the process of HIV-1 membrane fusion with the host cell the viral core is 
released into the cytoplasm and a poorly characterised process described as uncoating 
takes place (FIG 3). It is believed that HIV-1 cores disassemble in the cytoplasm since 
HIV-1 CA is not found in nuclear fractions of infected cells [70]. However, some 
evidences suggest that uncoating occurs in proximity to nuclear pore complexes [71]. In 
addition, recent work suggest that HIV-1 CA is involved in nuclear import of HIV-1 
pre-integration complexes, suggesting that fractions of CA might enter the nucleus [72]. 
A B C 
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It is at the early step after infection that cellular host proteins like TRIM5α, Cyclophilin 
A and probably other yet unidentified factors act to enhance or inhibit the virus. 
However, the molecular details of the mechanisms of these factors remain unclear.   
For successful infection retroviruses need to transcribe their genomic RNA into a 
double stranded DNA molecule, which is then integrated into the host genome. All 
retroviruses undergo the process of reverse transcription shortly after they have entered 
the target cell and this process is normally completed within 8 to 12 h after infection 
[73]. Reverse transcription occurs in a complex of viral RNA and proteins, referred to as 
the reverse transcription complex (RTC) that is thought to arise as a result of viral 
uncoating [70].  
 
FIG 6 Structure of the HIV-1 reverse transcriptase  
The picture shows the structure of the p51/ p66 reverse transcriptase heterodimer with a DNA template. 
The structure is a typical right handed polymerase structure with thumb, palm and finger domains. The 
connection and RNaseH domains are indicated. Figure derived from [74]. 
 
The detailed molecular process of reverse transcription is depicted in FIG 7. Reverse 
transcription (RT) is mediated by the viral reverse transcriptase, an asymmetric p51/ 
p66 heterodimer, which possesses two different catalytic activities, a DNA polymerase 
and a RNaseH activity for RNA digestion of RNA:DNA hybrids (FIG 6). The catalytic 
sites for both activities are found in the p66 form and the p51 appears to be structurally 
important. 
Reverse transcription is initiated at the 3’ end of a tRNA bound to the primer-binding 
site (PBS) located close to the 5’ end of the HIV-1 RNA (FIG 7). For HIV-1 it is the 
tRNALys3 that binds to the PBS and acts as a primer for reverse transcriptase. Selective 
packaging of tRNALys3 into budding virions is likely to be mediated by the lysyl-tRNA 
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synthetase that binds tRNALys3 and interacts directly with Gag during virus assembly 
[75]. The enzyme reverse transcriptase first synthesises complementary DNA of 
negative polarity (-) towards the 5’ end of the RNA transcribing the RU5 region. During 
this process the RNaseH enzyme activity of the reverse transcriptase degrades the RNA 
strand of the newly generated RNA-DNA hybrid causing a single strand 3’ DNA RU5 
overhang also called (-) strong-stop DNA. The repeat region (R) of this overhang is able 
to anneal to the complementary 3’ RNA repeat region either of the same molecule or 
with the second packaged RNA molecule. This strand exchange provides the virus with 
the ability to recombine. Annealing of the synthesised DNA to the 3’ RNA R region 
serves to prime the RNA dependent DNA synthesis (RDDP). Elongation continues until 
it reaches the 5’ RNA PBS. The (+) strand RNA in the DNA-RNA hybrid is then 
degraded by the RNaseH activity of reverse transcriptase, however a region close to the 
3’ RNA end possessing a ~11 nt long polypurine tract (PPT) escapes this degradation 
and functions as a priming site for the DNA-dependent polymerase activity of the 
reverse transcriptase (DDDP). This leads to the synthesis of the 3’ end of the (+) DNA 
strand including the entire U3RU5 region as well as 18 nt of the tRNA sequence that is 
complementary to the PBS. In addition, HIV-1 has a second, more central, PPT region 
also mediating (+) DNA synthesis. The positive strand DNA synthesis stops when 
reverse transcriptase encounters a modified base in the tRNA sequence. The generated 
(+) DNA sequence that is complementary to the 3’ end of the bound tRNA is called (+) 
strong-stop DNA. RNaseH activity degrades the tRNA primer and the RNA PPT 
causing a single stranded 3’ (+) DNA overhang of the PBS. This sequence can anneal 
with the complementary PBS of the (-) strand DNA causing the second “strand 
exchange” and thereby creating a circular intermediate form of viral DNA. A linear 
double stranded DNA molecule with two identical LTRs is synthesised by the reverse 
transcriptase by strand displacement. During this process an aberrant circularised form 
with a single LTR (1-LTR circle) can form (FIG 3). Furthermore, ends of the linear 
DNA molecule can be joined by cellular DNA repair enzymes of the non-homologous 
end joining pathway, creating a second circular form denoted as 2-LTR circles (FIG 3). 
The formation of 2-LTR circles is seen as a marker for nuclear entry, since the ligases 
involved, Ku70 and Ku80, are nuclear enzymes [76].  
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FIG 7 The process of reverse transcription of HIV-1   
The HIV-1 RNA is reverse transcribed into DNA by the RNA dependent polymerase (RDDP) activity of 
the reverse transcriptase starting at the 3’ end of tRNA primer. The 5’ RU5 is transcribed and the RNA is 
degraded by the RNaseH activity of the reverse transcriptase (step 1 and 2). The first inter- or 
intramolecular strand exchange (sometimes referred to as the first jump) leads to the initiation of reverse 
transcription of the negative DNA strand from the 3’R up to the PBS in the 5’ RNA region (steps 3 - 5). 
A polypurine tract (PPT) initiates the DNA dependent polymerisation (DDDP) of the positive DNA 
strand (step 5-6). Additional initiation of positive DNA strand synthesis occurs along the negative DNA 
strand at a central PPT. In the second strand exchange (second jump), the 3’ PBS of the negative DNA 
strand anneals with the 3’ PBS of the positive DNA strand and DDDP occurs via strand displacement. 
Linearised double stranded viral DNA with two identical LTRs, one at each end, is able to integrate into 
the host genome. In addition, ligation of the linear genome before integration can lead to 2-LTR circle 
formation and recombination can create 1-LTR circles (not shown).  
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1.4.3. Nuclear import of HIV-1 PICs 
To integrate their genomes successfully into the host, retroviruses need to enter the 
nucleus of an infected cell (FIG 3). In contrast to MLV, HIV-1 is able to infect 
non-dividing cells but the molecular details underlying this difference remain poorly 
understood [77]. Studies have shown that RTCs from MLV contain capsid (CA), 
integrase (IN) and reverse transcriptase proteins, whereas CA was not detected in HIV-1 
RTCs [70, 73, 78]. HIV-1 RTCs also contain the viral protein Vpr, as well as matrix 
(MA), reverse transcriptase and integrase [70, 79]. The absence of CA protein in cell 
fractions of HIV-1 infected cells with high reverse transcriptase activity as well as the 
inability to immunoprecipitate viral DNA with anti-CA antibodies suggests that if at all, 
very low numbers of CA protein are associated with HIV-1 RTCs [79]. In contrast, 
more recent studies suggested that the HIV-1 CA protein may be directly involved in 
the process of infecting non-dividing cells at a step past nuclear entry. For example, a 
study using HIV-1, in which the MA-CA coding region was replaced by MLV MA-
p12-CA, showed that the chimaeric virus was inhibited in infecting aphidicolin arrested 
cells [80]. Replacement of the HIV-1 MA by MLV MA-p12 however had no effect on 
infecting non-dividing cells [80]. Furthermore, CA mutations altering cyclophilin A 
sensitivity of HIV-1 seem to affect the ability of the virus to infect non-dividing cells 
[81]. These observations imply that at least some CA proteins may be present in the pre-
integration complex (PIC) entering the nucleus [72]. 
Every viral protein present in the HIV-1 PIC, apart from reverse transcriptase, has been 
proposed to be involved in mediating nuclear entry. The first protein to be implicated in 
nuclear import via two different internal nuclear localisation signals (NLS) was the 
matrix protein (MA/ p17) [82, 83]. However, tagged MA protein is not localised to the 
nucleus [84] and pseudotyped HIV-1 particles with a non-functional MA are still able to 
infect macrophages [85], suggesting that the matrix protein is dispensable for nuclear 
import of PICs.  
Vpr has been suggested to mediate HIV-1 PIC nuclear import in macrophages due to its 
karyophilic property and by binding to members of the importin alpha family [86, 87]. 
Further studies showed that Vpr has two NLS motifs [88]. Moreover, in vitro studies 
using digitonin-permeabilised cells suggested that Vpr is the key regulator for nuclear 
import of HIV-1 PICs. These studies demonstrated that Vpr mediates the docking of the 
PICs to nuclear pore complexes (NPC) and that recombinant Vpr provided in trans 
could restore 2-LTR circle formation of Vpr defective virus, suggesting 
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complementation of nuclear import [89, 90]. An unconventional mechanism of Vpr 
function proposed to promote HIV-1 infection in arrested cells is the herniation of the 
nuclear envelope [91]. The importance of MA and Vpr in HIV-1 infection remains 
controversial and several reports have shown that disruption of nuclear localisation of 
MA and Vpr is insufficient to abolish infection of cell cycle arrested cells or primary 
macrophages [92, 93]. Evidence that a third factor is involved in mediating nuclear 
import in non-dividing cells came from a study in which high doses of HIV-1 with a 
NLS deleted MA and without Vpr were used to infect terminally differentiated 
macrophages. The data showed that high virus doses could overcome the defect caused 
by the deletions [94]. However, additional mutation of the HIV-1 integrase abolished 
nuclear translocation suggesting a role for this protein in nuclear entry. The integrase 
mediated import was dependent on the karyopherin alpha import pathway [95].  
 
 
 
FIG 8 Nuclear import of HIV-1 pre-integration complexes (PICs)  
A) Pathway of HIV-1 in a cell shortly after infection. Virions fuse with the plasma membrane and the 
core is delivered into the cytoplasm. Uncoating releases viral RNA which is reverse transcribed into DNA 
in a complex with proteins (RTC). After synthesis of viral DNA the pre-integration complex (PIC) is 
formed that contains at least matrix, Vpr, integrase and reverse transcriptase and probably multiple 
cellular factors (e.g. LEDGF/ p75). Intracellular trafficking of RTCs and PICs towards the nucleus 
appears to be via microtubules [96]. Nuclear entry is believed to occur at the nuclear pore complex 
(NPC). Binding of LEDGF/ p75 to integrase in the cytoplasm may facilitate nuclear translocation of the 
PICs. Integration site specificity appears to be directed by LEDGF/ p75. MTOC, microtubule 
organisation centre. Figure derived from [97]. 
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Recent data proposes a model in which integrase binding to the lens-epithelium-derived 
growth factor (LEDGF/ p75) (see 1.4.4.), a component of functional HIV-1 PICs, 
enhances their nuclear entry [98, 99].  
In addition to MA, Vpr and IN proteins, the triple strand DNA structure found in the 
central polypurine tract (PPT) after reverse transcription referred to as the DNA flap, 
has also been reported to play a role in nuclear import [100]. Deleting or mutating this 
cis acting element, leads to the accumulation of linear unintegrated DNA at the vicinity 
of the nuclear membrane and significantly impairs nuclear import [100]. Interestingly, it 
has been suggested that the DNA flap promotes uncoating of HIV-1 at the nuclear pore 
[71]. In such a model the capsid shell is shed directly at the NPC followed by nuclear 
translocation of the PIC. However, like the whole field of nuclear import these 
observations are controversial and some work suggests wild type levels of HIV-1 
replication in the absence of the central DNA flap [101]. Studies using an in vitro 
nuclear import assay have suggested that tRNAs with defective 3’CCA ends are 
transported into the nucleus in an energy and temperature dependent manner and can 
promote HIV-1 PIC nuclear import [102]. How this is achieved and the physiological 
relevance of this observation is currently unclear. 
Early studies suggested that in primary macrophages HIV-1 PICs gain access to the 
nucleus using an active, RanGTP dependent transport mediated by importin-7 binding 
to integrase [103]. SiRNA mediated reduction of importin-7 levels however only 
reduces HIV-1 nuclear import by a few fold, suggesting that importin-7 plays a minor 
role. In addition, importin-7 is not involved in nuclear import of other lentiviruses 
including HIV-2, SIVmac and EIAV [104]. A genome wide siRNA screen aiming to 
identify host factors involved in the HIV-1 life cycle revealed the importance of the 
karyopherin transportin 3 (transportin-SR2/ TNPO3) for nuclear entry of HIV-1 but not 
MLV [105]. Furthermore, in analogy to a study on Drosophila homologues, this study 
suggested that the nuclear pore proteins Nup153 and Nup358/ RanBP2/ Cyp358 are 
involved in nuclear entry by interaction with TNPO3 [106]. In agreement with this 
prediction, TNPO3 and Nup358 also appeared in a second RNAi screen for HIV-1 
co-factors [107]. TNPO3 was first identified in a yeast-two hybrid screen as a binding 
partner for HIV-1 IN and RNAi mediated reduction of TNPO3 reduced HIV-1 and 
HIV-2 replication by 3 to 4-fold [108]. Interestingly, the yeast orthologue of TNPO3, 
MTR10, seems to promote tRNA shuttling from the cytosol back to the nucleus [109]. 
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The observation that some tRNAs enhance HIV-1 nuclear import may be connected to 
the function of TNPO3 in promoting HIV-1 nuclear import [102]. 
 
1.4.4. Integration of HIV-1 DNA into the host genome 
For a productive infection the viral double stranded linear DNA molecule has to 
integrate into the host genome establishing a provirus (FIG 3). Integration occurs with 
the activity of the viral enzyme integrase (IN), p32 [110]. Recently, IN inhibitors have 
become available for treatment of HIV-1/AIDS and these are expected to complement 
protease and reverse transcriptase inhibitors. 
HIV-1 IN is a 32 kDa protein that is derived from the Gag-Pol precursor. Integrase 
consists of an N-terminal zinc-binding domain that is likely to support multimerisation, 
a central catalytic domain and a C-terminal DNA binding domain, which associates 
non-specifically with DNA. Integrase promotes two distinct reactions that are necessary 
for virus DNA integration. The first reaction takes place in the cytosol and is the 3’ 
processing in which a conserved CA dinucleotide is endonucleolytically liberated from 
the 3’ ends of the double stranded viral DNA (FIG 9BII). Thereby, two reactive 
hydroxyl-groups are generated, which attack a phosphodiester bond in the host genomic 
DNA (FIG 9BIII). In the process of 3’ end-joining integrase ligates the viral DNA into 
the host DNA, creating a single-stranded DNA segment of five base pairs at each end of 
the host DNA and a two nucleotide 5’ viral DNA flap. The cellular DNA repair 
machinery fills the gaps and ligates the synthesised DNA into the host genome [111].  
In addition to the 3’ processing and 3’ strand transfer reaction, two other reactions 
catalysed by integrase have been observed in vitro. The first reaction is a process 
referred to as disintegration and is the reverse of the 3’ strand transfer reaction, however 
there is currently no data for its in vivo relevance. Second, tetrameric integrase 
complexes have been shown in vitro to cleave small oligonucleotides possessing the 
junction sequence between two LTRs that is seen in naturally occurring 2-LTR circles, 
suggesting that 2-LTR circles may not represent a dead end infection [112]. 
Interestingly, when integration is abolished for example by mutating integrase, 2-LTR 
circles are increased suggesting that this function may play a role in ensuring efficient 
integration in vivo [113]. HIV-1 does not integrate randomly into the host genome but 
prefers transcriptionally active sites [114]. To target sites for integration HIV-1 exploits 
specific host factors. 
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FIG 9 Integration of HIV-1 DNA into the cellular host genome  
A) The process of integration of the HIV-1 DNA into the host genome is depicted. Double stranded viral 
DNA is processed by integrase and imported into the nucleus in the form of the pre-integration complex 
(PIC). Integration into the host genome creates the provirus. B) The viral DNA recombination sites (att) 
are depicted (I). Integrase creates a two-base pair 5’ overhang at each site of the viral DNA by nucleolytic 
liberation of a conserved CA dinucleotide from the 3’ end, a reaction called 3’ processing (II). After 
nuclear import the generated hydroxyl groups at the 3’ end attack a DNA phosphodiester bond in the host 
genome DNA in a process referred to as 3’ end joining (IV). This leads to a five-base single-stranded 
sequence at each end of the host acceptor DNA and a two nucleotide 5’ overhang (flap) of the integrating 
provirus. Host cell DNA repair enzymes generate double stranded DNA, and the 5’ flap is cleaved off 
generating the fully integrated provirus (V). Figure adapted from [115]. 
 
Emerin, an integral inner-nuclear-envelope protein, has been proposed to be important 
for HIV-1 integration in macrophages [116]. A recent study investigating cells derived 
from emerin knockout mice however challenged this study and suggested that emerin 
and the protein lamina-associated polypeptide 2alpha (LAP2α) are dispensable for 
HIV-1 infection [117]. The barrier to auto-integration factor (BAF) and possibly the 
high-mobility group protein A1 (HMG-I(Y)/ HMGA1) may also be involved in 
integration of HIV-1 viral DNA. Purification of PICs and subsequent addition of cell 
fractions, initially identified HMGA1 to be important for HIV-1 infection [118]. A 
similar assay identified BAF binding to viral DNA, thereby facilitating inter-molecular 
integration and inhibiting auto-integration [119]. This study also investigated the impact 
of HMGA1 and bovine RNaseA, a non-specific DNA-binding control, and found that 
both proteins restored in vitro integration of purified PICs at very high concentration, 
suggesting that the function of HMGA1 is non-specific. BAF non-specifically binds 
double stranded DNA and co-immunoprecipitates with the HIV-1 proteins Gag and MA 
and may be packaged into virus at up to three copies per virion [120]. However, the 
exact mechanism of BAF function and its physiological relevance during infection is 
not understood. 
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Despite controversial observations in the early stages after the discovery of the integrase 
binding protein LEDGF/ p75, evidence for a functional role of this protein in enhancing 
and directing integration is increasing. LEDGF/ p75 binds integrases from HIV-1 and 
other lentiviruses but not from non-lentiviral retroviruses [99, 121]. SiRNA mediated 
reduction of LEDGF/ p75 expression or gene deletion in mice, decreases integration of 
HIV-1 and ablates the preference for transcriptionally active sites in the genome [122, 
123]. Directed integration seems to be concerted by an interaction of LEDGF/ p75 with 
the HIV-1 IN because mutations in IN that affect LEDGF/ p75 interaction also impair 
HIV-1 integration [124]. Furthermore, a stable functional complex of dimeric LEDGF/ 
p75 and a tetrameric full-length integrase molecule could recently be reconstituted in 
vitro. This complex showed enhanced integration activity as compared to the integrase 
alone [125]. The study also revealed structural insights into the interaction of IN with 
LEDGF/ p75 and viral and host cell DNAs (FIG 10). 
 
 
 
 
FIG 10 Structure of HIV-1 integrase bound to the cellular co-factor LEDGF/ p75  
A) Depicted is the 3-dimensional structure of an HIV-1 integrase tetramer (orange) associated with a 
LEDGF/ p75 dimer (grey). B) The viral DNA (yellow) and the host cell target DNA (red) are shown 
before 3’ strand transfer reaction. Figure derived from [125]. 
 
A B 
1. INTRODUCTION 29
1.4.5. Transcription and the function of Tat 
After the virus has established a provirus, transcription of HIV-1 is mediated by the 
cellular RNA polymerase II (RNA Pol II) in a similar way to the transcription of 
cellular host genes. HIV-1 transcription occurs in two distinct phases, an early phase 
independent of transactivation and a late phase that depends on the presence of the viral 
protein Tat. Transactivation of transcription by Tat is an important step in the HIV-1 life 
cycle (FIG 11). A region located between nucleotides +1 and +59 downstream of the 
HIV-1 LTR transcription start site forms the transactivating responsive region (TAR) in 
synthesised RNAs [126, 127]. During transcription the RNA adopts a stem loop 
structure in this region. RNA Pol II transcription elongation is mediated through Tat 
binding to TAR and the recruitment of the cellular transcription elongation factor 
P-TEFb [128]. P-TEFb consists of CyclinT1 and the cell cycle dependent kinase 9 
(Cdk9) that mediates the hyperphosphorylation of the C-terminal domain (CTD) of the 
RNA Pol II [129].   Hyperphosphorylation of the CTD leads to efficient transcription 
elongation by RNA Pol II. Efficient transcription of the HIV-1 provirus requires the 
binding of different transcription factors upstream of the transcription start site, e.g. NF-
κB and Sp1 (FIG 11). In addition to the well studied activity of Tat to initiate 
transcription elongation with the help of P-TEFb by binding to the TAR stem loop, Tat 
may also enhance the assembly of the transcription pre-initiation complex by promoting 
TATA-binding protein (TBP) association with the TATA box [130]. The positive effect 
was observed for TBP recruitment to the TATA box, however an increase in 
TBP-associated factors (TAFs) was not observed [130]. Interestingly, whilst Tat 
transactivates HIV-1 transcription it also can have a repressive effect on transcription of 
cellular genes (e.g. MHC class I genes) by binding to TAFII250 and inhibiting its 
histone acetyl transferase activity [131]. In addition, Tat functions to inhibit repressors 
of HIV-1 transcription like the cleavage and polyadenylation specificity factor (CPSF) 
complex that has been demonstrated to bind and inhibit the HIV-1 LTR promoter [132]. 
In fact, Tat interacts with a variety of factors involved in transcriptional control but the 
importance of these interactions remains unclear. 
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FIG 11 Transactivation of transcription by HIV-1 Tat  
A) The HIV-1 LTR promoter is shown. Upstream of the transcription initiation site NF-κB and Sp1 
binding sites as well as a TATA box can be found. Downstream of the transcription start site the 
transactivating-responsive region (TAR) is located. B) HIV-1 transcription initiation occurs by NF-κB 
and Sp1 binding and assembly of the large RNA polymerase II complex at the TATA-binding protein 
(TBP). Tat binds to P-TEFb, a transcription elongation factor consisting of cyclinT1 and cdk9, which 
itself associates with the RNA Pol II transcription initiation complex. C) Transcription is stalled after 
TAR has been transcribed until Tat binding to both P-TEFb and TAR initiates P-TEFb dependent 
hyperphosphorylation of the C-terminal domain of RNA Pol II promoting transcription elongation. Figure 
adapted from [133]. 
 
The HIV-1 provirus is established in the context of host cell chromatin. Immediately 
up-/ and downstream of the integration site nucleosomes are formed, repressing HIV-1 
transcription. To ensure efficient transcription, chromatin-remodelling enzymes have to 
be recruited that modify the downstream nucleosome. Tat recruits histone 
acetyltransferase proteins including p300/CREB-binding-protein (CBP), the p300/CBP-
associated factor (PCAF) and the general control nonderepressible 5 protein (GCN5) 
[134, 135]. Tat itself is the target for modifications by PCAF and GCN5, and Lys-28 
acetylation of Tat has recently been demonstrated to be important for stabilising the 
TAR-Tat-P-TEFb complex [136]. Furthermore, Tat is also subject to deacetylation by 
SIRT1, which may be a way to recycle acetylated Tat [137]. In addition to acetylation 
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of Tat, acetylation of the N-termini of histone proteins H3 and H4 located in the 
nucleosome downstream of the transcription initiation site enhances HIV-1 provirus 
transcription. Further evidence for chromatin-remodelling to ensure efficient HIV-1 
transcription is the recruitment of the ATP-dependent SWI/SNF chromatin-remodelling 
complex that appears to be a co-factor for Tat transactivation of transcription [138].  
  
1.4.6. Rev dependent export of partially spliced and unspliced mRNAs 
To ensure the production of virus proteins, mRNAs synthesised in the nucleus need to 
be exported into the cytoplasm. Molecular interaction partners for mRNA export are 
depicted in FIG 12. Cellular mRNAs are exported with the help of the two proteins Tap 
and Nxt1, which bind mRNA in the nucleus as a heterodimer. Cellular mRNAs bind to 
the host cell protein UAP56, which associates with the protein Aly that in turn recruits 
the Tap/ Nxt1 heterodimer [139]. Nuclear mRNAs are therefore loaded with a variety of 
proteins before they exit the nucleus to ensure correct processing and transport, and to 
prevent the export of unspliced or partially spliced mRNAs. For efficient nuclear 
mRNA export, a process of remodelling during which the bound proteins dissociate 
from the mRNA is important. Cellular mRNAs are bound by the DEAD box helicase 
Dbp5, which interacts with proteins of the NPC and mediates translocation and 
remodelling of the mRNA as well as subsequent translation termination [140, 141]. 
Some simple retroviruses like Mason Pfizer monkey virus (MPMV) exploit this 
pathway by directly recruiting Tap/ Nxt1 to their constitutive transport element (CTE), a 
cis acting sequence found in their unspliced mRNAs. 
In contrast to most cellular mRNAs, HIV-1 generates multiple singly spliced and 
unspliced mRNAs (FIG 13). The HIV-1 early transcripts Tat and Rev, as well as Nef 
are multiply spliced and the processed mRNAs are exported from the nucleus into the 
cytoplasm via the cellular mRNA export pathway. The HIV-1 Rev and Tat protein are 
both imported into the nucleus after their synthesis. The export of unspliced full-length 
viral RNAs, that encode the Gag and GagPol polyproteins or serve as genome RNA that 
is packaged into virions, is dependent on the viral Rev protein. Viral mRNAs encoding 
Env and Vpu, Vif, Vpr and Tat are singly spliced, and their nuclear export is also 
dependent on Rev. Rev binds to the Rev-responsive-element (RRE), a very conserved 
cis acting region in the Env coding region (FIG 2) that forms a strong secondary 
structure with several stem loops [142]. Rev binds the stem-loop IIB, initially as a 
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monomer followed by further association of Rev monomers through Rev-Rev 
interactions [143]. Oligomerisation of Rev at the RRE has been suggested to be 
important for its function and as many as eight molecules can bind to the RRE [144, 
145]. Since Rev’s interaction with the RRE is essential for nuclear export of HIV-1 
RNAs, it presents a suitable target for drug development. A dominant negative Rev 
protein, RevM10, has been investigated as a suitable drug. However, virus escape 
mutants arise by changing their RRE conformation [146, 147].  
Partially or unspliced cellular mRNAs are bound by splicing commitment factors in the 
nucleus, which cause their nuclear retention in the Tap/ Nxt1 pathway. To circumvent 
this block of singly- or unspliced viral RNA export, HIV-1 uses a different export 
pathway involving the cellular proteins chromosome region maintenance 1 (Crm1) and 
the DEAD box RNA helicase DDX3. In contrast to the Tap/Nxt pathway, Crm1 
mediated export is dependent on the GTPase Ran and can specifically be blocked by the 
drug leptomycin B. The Crm1 pathway is usually used to export proteins, small nuclear 
RNAs and ribosomal RNAs and is distinct from the pathway used for completely 
spliced HIV-1 RNAs. In the nucleus Crm1 associates with RanGTP and replaces the 
eukaryotic initiation factor 5A (eIF5A) that is bound to the viral Rev protein [148]. The 
Rev protein contains a nuclear export sequence (NES) that is recognised by Crm1. In 
addition, DDX3 binds to the RNA/Rev/Crm1/RanGTP complex as well as to proteins of 
the NPC, suggesting that it has a similar role to Dbp5 to support RNA remodelling after 
or during nuclear export [149]. The nuclear RNA/Rev/Crm1/DDX3/RanGTP complex 
associates with FG repeat nucleoporin proteins at the NPC, mediating the export of the 
complex. RanGAP-mediated RanGTP hydrolysis in the cytoplasm leads to the 
disassembly of the complex and initiates subsequent steps of RNA translation or 
transport of genomic RNA for packaging into virions. Rev and Crm1 cycle between the 
cytoplasm and nucleus so that a constant export of viral RNAs is ensured. Genomic 
RNAs are translated into the Gag and GagPol polypeptides or packaged as non-
covalently linked dimers into newly forming virions. Packaging is achieved by the 
interaction of a specific nucleocapsid (NC) protein domain in Gag with the cis acting Ψ 
site located near the 5’ end of the genomic RNA. Dimerisation of the genomic RNAs is 
important for efficient packaging and generation of infectious HIV-1 [150]. However, 
the subcellular site for HIV-1 genomic RNA dimerisation is not known. 
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FIG 12 HIV-1 nuclear RNA export compared to the cellular mRNA export pathway  
A)  Transcribed and correctly spliced cellular mRNAs are exported from the nucleus by binding of TAP 
and Nxt1. B) The HIV-1 Rev protein binds viral RNAs at the RRE cis-sequence and recruits Crm1 and 
DDX3, which mediate nuclear export of singly and unspliced RNAs. Figure derived from [151]. 
 
 
 
FIG 13 Splicing of the HIV-1 RNA  
HIV-1 splice sites are shown. HIV-1 has got at least four different 5’ splice sites and at least eight 
different splice acceptor sites (3’ splice sites). Partially spliced mRNAs and unspliced genomic RNA have 
the RRE cis-element and are exported in a Rev dependent manner, whereas Tat, Rev and Nef encoding 
mRNAs are exported in a Rev independent way. Figure derived from [152]. 
A B 
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1.4.7. Gag trafficking and HIV-1 budding via the cellular ESCRT machinery 
To complete their life cycle, viruses need to ensure the efficient production and release 
of infectious virus particles. For the generation of virus particles the Gag protein has to 
be delivered to Env containing budding sites at the plasma membrane.  
 
    
FIG 14 Gag interaction with a genomic RNA dimer and trafficking  
A) Synthesis of Gag and GagPol leads to accumulation of the proteins at the plasma membrane and 
interaction with a dimer of genomic viral RNAs mediating its packaging into newly formed virions. B) 
HIV-1 Gag consists of matrix (MA), capsid (CA), p2, nucleocapsid (NC), p1 and p6 and multimerisation 
involves domains in MA, CA-p2 and NC. Figure derived from [153]. 
 
Newly synthesised Gag and GagPol proteins are co-translationally modified with the 
14-carbon fatty acid myristate. Myristyolation occurs at the N-terminus of the MA 
protein and this modification is important for membrane association of Gag as well as 
particle formation. Membrane association of Gag is induced by the exposure of a 
myristate group in MA [154]. Gag multimerisation at the plasma membrane is mediated 
by regions in NC, CA-p2 and MA [155]. HIV-1 Gag proteins associate at the plasma 
membrane with lipid microdomains, called lipid rafts. Gag trafficking to the plasma 
membrane may involve intermediate compartments in cells defined as multivesicular 
bodies (MVBs). Studies have shown that AP-1, AP-2 and AP-3, members of the 
clathrin adaptor protein (AP) complexes interact with Gag. For example, AP-3 has been 
suggested to be important for Gag trafficking from MVBs to sites of assembly at the 
plasma membrane. AP-3 depletion caused Gag accumulation in MVBs and aborted 
infectious particle production [156-158]. Gag localisation to the plasma membrane may 
also be sensitive to phoshpatidylinositol-4,5 biphosphate (PIP2) levels [159]. When a 
constitutively active form of the cellular protein Arf6 was expressed, endosomal 
structures with a high content of PIP2 were formed and virions budded into these 
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compartments, suggesting a similar role for plasma membrane associated PIP2 in direct 
Gag recruitment [159]. 
HP68 is a protein that has been proposed to be involved in the formation of the Gag 
core during virus assembly [160]. It has been suggested that HP68 binds to Gag at virus 
assembly sites and its dissociation from Gag is important for the following steps in virus 
assembly [161]. Another protein that may be involved in virus budding is TIP47. It has 
been suggested to be required for Gag association with Env at virus budding sites and to 
be involved in Env trafficking [162, 163]. However, since this initial report no further 
results on its function in HIV-1 budding have been published.  
Some membrane associated HIV-1 Gag is ubiquitinated and Gag ubiquitination is 
important for virus budding [164, 165]. Ubiquitination of Gag is highly dependent on its 
membrane association but the ubiquitin ligase mediating Gag ubiquitination has yet to 
be identified [165]. Nedd4-like E3 ubiquitin ligases may be involved in HIV-1 Gag 
ubiquitination since some members associate with retroviral Gag proteins [166]. The 
Nedd4-like E3 ubiquitin ligases may link Gag ubiquitination with the recruitment of the 
budding machinery described below. In addition, de-ubiquitinating enzymes like the 
associated molecule with the SH3 domain of STAM (AMSH) may be involved in 
regulating Gag ubiquitination at sites of virus assembly [167].  
Retroviruses, including HIV-1, exploit the cellular endosomal sorting complex required 
for transport (ESCRT) machinery, which is comprised of three multi-subunit protein 
complexes ESCRT-I, II and III. Each of these complexes consists of a variety of 
different ESCRT proteins (FIG 15). The ESCRT machinery was first described in yeast 
as an important component for sorting of cargo into the yeast vacuole. This work has 
been translated to mammalian cell biology and important roles have been found for 
cargo sorting into MVBs, abscission during cell division and the budding of enveloped 
viruses at the plasma membrane. HIV-1 and other retroviruses possess short sequence 
motifs in their Gag proteins, which are called late domains (L-domains) and function to 
regulate virus budding by recruiting the ESCRT machinery. Mutation of these domains 
leads to the accumulation of virions that are unable to complete budding and are 
connected to the cell membrane by thin membrane stalks [168]. HIV-1 possesses 
multiple L-domains in its p6 protein, located at the C-terminus of Gag (FIG 2 and FIG 
15). The PTAP motif found in the N-terminus of p6 binds the ubiquitin E2 variant 
(UEV) domain of tumour susceptible gene 101 (Tsg101), whereas the LYPXL motif in 
the C-terminus of p6 recruits the V-domain of ALG-2 (apoptosis-linked gene 
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2)-interacting protein X (Alix) [169-172]. Tsg101 and Alix are key players in the 
assembly and function of the ESCRT machinery and recruit ESCRT-I and ESCRT-III 
complexes, respectively. SiRNA mediated depletion of either of these two important 
proteins, or expression of dominant negative versions of proteins involved in the 
budding pathway, e.g. Vps4, results in a virus budding phenotype that is 
indistinguishable from viruses mutated in their L-domains [170]. Moreover, 
overexpression of Alix can rescue HIV-1 that is defective in recruiting Tsg101 due to 
the disruption of its PTAP motif and this rescue is independent of Tsg101 expression. 
This suggests that Alix’s function for wild type virus budding may be of redundant 
nature and not via the ESCRT-I machinery [173]. Furthermore, Alix also binds to the 
HIV-1 nucleocapsid via its BroI domain, which was suggested to be important for 
budding [174, 175]. In addition, budding of PTAP
 
or LYPXL mutated HIV-1 can be 
rescued by overexpression of a naturally occurring N-terminally truncated isoform of 
the Nedd4 E3 ubiquitin ligase called Nedd4L/Nedd4-2 or Nedd4-2s [166, 173]. This 
isoform binds to a region in HIV-1 Gag localised to the C-terminus of CA and the p2 
protein. The exact binding site and the molecular mechanism however remain to be 
discovered, but the rescue seems to involve the assembly of the ESCRT-I machinery 
since Tsg101 reduction reduced the effect [173]. Alix recruits the ESCRT-III complex, 
which consists of a number of Chmp proteins that mediate the final step of membrane 
scission. After the virion has budded from the plasma membrane the ESCRT-III 
machinery is disassembled by the Chmp dependent recruitment of Vps4, a member of 
the AAA-ATPases, associated with a variety of activities.  
The subcellular site of HIV-1 assembly has been very much discussed over the last 
years. In primary macrophages HIV-1 was suggested to assemble into cellular 
compartments, which showed markers of late endosomes [176]. Later studies however 
showed that this compartment is structurally a pre-existing invagination of the plasma 
membrane that may present a special compartment in macrophages [177]. Contradicting 
results were obtained however by other labs, showing that also in macrophages HIV-1 
assembled at the plasma membrane [178]. The use of L-domain mutants in 
macrophages may help to elucidate the real site of assembly, however these experiments 
have yet to be performed.   
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FIG 15 The ESCRT machinery and budding of HIV-1  
The steps occurring at the plasma membrane before HIV-1 budding are shown. ESCRT-I is recruited to 
Gag by interaction of Tsg101 with the PTAP motif in HIV-1 Gag p6. Alix interacts with the LYPXL 
motif in p6 and recruits the ESCRT-III machinery via interaction with Chmp4 proteins. Chmp proteins 
are essential for the membrane scission and liberation of HIV-1 virions and recruit the ATPase Vps4. 
Figure adapted from [179]. 
 
 
1.4.8. Maturation 
As soon as the virion has budded from the plasma membrane a process referred to as 
maturation takes place. The viral protease present in the few GagPol proteins that have 
been packaged into the virus cleaves Gag and GagPol proteins at distinct cleavage sites 
and liberates the proteins that constitute the internal structure of the virion, namely NC, 
CA, MA as well as the enzymes necessary for the next round of infection, integrase, 
protease and reverse transcriptase (FIG 16A and B). GagPol polyproteins arise when 
~5% of the ribosomes translating Gag shift the reading frame at the end of Gag leading 
to further translation of Pol. Five different processing sites for the viral protease are 
located in Gag and all have been demonstrated to be essential for the infectivity of 
virions [180]. The order of cleavage is conserved starting with processing between SP1 
and NC and ending with cleavage between CA and SP1 [181] (FIG 16C). Thus, 
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protease activity is the target for several drugs used in highly active antiretroviral 
therapy (HAART).  
Liberated CA proteins form hexameric and pentameric fullerene structures, which build 
the cone shaped core of the mature virion (FIG 28A). Necessary for this structural 
maturation are conformational changes in the N- and C-terminus of cleaved CA. 
Nucleation of core assembly therefore depends on the correct cleavage by the virus 
protease.  
 
 
 
FIG 16 Maturation of HIV-1  
A) After budding from the plasma membrane HIV-1 virions are immature and contain uncleaved Gag and 
GagPol proteins. The viral RNA dimer is associated with the NC domain of Gag. Internal cleavage events 
mediated by the viral protease lead to maturation of the virus. B) The mature virion contains a cone 
shaped core built of CA proteins burying the viral RNA dimer with attached NC proteins. MA proteins 
associate with the internal site of the viral membrane. Not shown are several other viral (Nef, Vpr) and 
cellular (e.g. CypA) proteins that also get packaged into the virions. C) Gag protein before cleavage. 
Protease cleavage sites are indicated with arrows. The numbers show the order of cleavage. Figure 
adapted from [180].   
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1.5. Innate immunity against retroviruses 
Complex organisms have evolved many diverse ways to protect themselves from 
infection by pathogens, such as viruses or bacteria. The immune system is comprised of 
innate and adaptive arms and both are essential for efficient protection from pathogen 
infection. The innate immune system acts immediately after a virus has intruded an 
organism and includes for example the activation of the complement system and the 
production of interferons (IFNs), small molecules that are able to induce an antiviral 
state in the proximity of an infection. It is therefore an intracellular barrier that a virus 
encounters and it is important that it acts rapidly to limit virus replication and to provide 
time for the organism to induce the second arm of defence, the adaptive immune 
system. This acts via selection and expansion of T- and B-cells and the production of 
specific antibodies directed against the invading pathogen. The innate immune system 
of mammals also comprises a heterogeneous group of intracellular factors that are able 
to efficiently counteract viral infection in multiple ways. These factors, called restriction 
factors, constitute an intrinsic immune system, which counteracts an invading pathogen. 
In general these factors are interferon inducible and their expression is upregulated 
during early infection. They often act in a species-specific way, thus a restriction factor 
of one species usually does not strongly restrict viruses that infect the same species, 
however may block viruses from related species. Host and pathogen co-evolve, hence 
the evolution of each depends on the evolution of the other. The cell provides a 
restriction factor to act against a viral infection and the virus can evolve a 
countermeasure. Both, the restriction factor and the viral countermeasure provide a 
selective pressure on each other, often referred to as an evolutionary arms race. The 
antagonistic relationship between restriction factors and their viral countermeasures are 
often only poorly understood and the little information on the function and molecular 
mechanisms underlying restriction of viruses were mainly derived by studies on 
retroviruses. In this respect it is worth noting that some of the restriction factors are also 
attractive targets for drug development for diseases like AIDS [182]. 
Known retroviral restriction factors and viral countermeasures to bypass or inactivate 
these factors are depicted in FIG 17. A selection of these will be discussed in the 
following chapters.  
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FIG 17 Host retroviral restriction factors and viral countermeasures 
Cellular antiviral proteins are shown in red and retroviral countermeasures are shown in blue. Moesin 
regulates the formation of stable microtubules and blocks before initiation of reverse transcription [183]. 
Tripartite motif protein 5 isoform alpha (TRIM5α) restricts early infection by binding to CA structures of 
diverse retroviruses [184, 185]. Viruses escape restriction by changing CA residues (blue) interacting 
with TRIM5α. The TRIM5-cyclophilinA fusion proteins (TRIMCyp) found in owl monkeys and certain 
macaques bind to CA via their CypA domain [186, 187]. In addition, cyclophilin A levels impact on HIV-
1 infectivity in a CA dependent manner [81]. Friend virus susceptibility 1 (Fv1) restricts certain MLV 
strains after reverse transcription but prior nuclear entry in a CA dependent manner [188]. Similarly, 
fasciculation and elongation protein ζ-1 (FEZ1) blocks retroviruses after reverse transcription but before 
nuclear entry [189]. Tripartite motif protein 28 (TRIM28) restricts MLV transcription in mouse 
embryonic stem cells by binding to the proviral primer-binding site [190]. The eukaryotic translation 
initiation factor 3 subunit f (eIF3f) inhibits the 3’LTR processing of viral mRNAs [191]. CCCH-type zinc 
finger protein ZAP depletes viral cytoplasmic mRNAs by an unknown mechanism [192]. Tetherin (Bst-2, 
CD317) inhibits release of diverse enveloped viruses and is counteracted by HIV-1 Vpu [193]. Nef from 
SIVs has also been suggested to block tetherin [194]. APOBEC3G/F proteins get packaged into HIV-1 in 
the absence of the viral Vif protein and cause hypermutations in the viral genome after infection, as well 
as inhibit elongation of RT in infected target cells [195-197]. HIV-1 Vpr supports nuclear import and 
causes cell cycle arrest in G2 possibly by binding an unknown factor, which may also be the target of the 
HIV-2/SIVsm Vpx protein. Nef increases infectivity of released virions possibly by inhibiting an 
unknown restriction factor in the virus producing cell, maybe in a way like Vif inhibits APOBEC3G/F. It 
also may act directly in a positive way via dynamin-2 [198]. Many viral proteins (Vif, Vpr, Vpx, Vpu) 
and some cellular factors (TRIM5, TRIMCyp) mediate degradation via the ubiquitin-conjugating and 
proteasome pathway, which becomes more and more a focus of intrinsic antiviral defence of cells.  
Inhibitory roles of TRIM11 [199], TRIM15 [199], TRIM22 [200] and TRIM5 [201, 202] in HIV-1 
production remain controversial.  
1. INTRODUCTION 41
1.6. The accessory viral proteins Vif, Vpr, Vpu and Nef 
Simple retroviruses, e.g. MLV, encode the three major polyproteins Gag, Pol and Env. 
These three gene products are sufficient to ensure the successful life cycle of the virus. 
More complex retroviruses, e.g. lentiviruses, have evolved a subset of additional genes, 
referred to as accessory genes. Emerging data suggests that a major role of the HIV-1 
accessory proteins Vpu, Vif, Vpr and Nef is to counteract innate and adaptive immune 
pathways or to modulate them to benefit the virus. Often they are dispensable for 
replication in vitro, but important in vivo.  
 
1.6.1. HIV-1 Vpr causes cell cycle arrest 
The HIV-1 protein Vpr has been briefly discussed above as a part of the pre-integration 
complex. It is involved in G2 cell cycle arrest, apoptosis and possibly transactivation of 
transcription and counteraction of an antiviral protein in macrophages. Vpr is a 96 
amino acid long protein that is conserved across primate lentiviruses (FIG 2). 
Vpr interacts with the first 46 amino acids of the p6 domain of Gag and is thereby 
packaged into virions [203]. However, Vpr was also found in isolated HIV-1 cores in 
the absence of p6 [204]. Vpr packaging has been used to study early events of HIV-1 
infection by fusing a fluorophore onto Vpr [205]. Interestingly, in a recent study the 
fluorophore was replaced with a member of the APOBEC family, APOBEC3A, and this 
fusion protein showed an antiviral effect against HIV-1 and SIVmac upon infection of 
target cells [206]. In addition, Vpr fusion proteins with either chloramphenicol 
acetyltransferase enzyme or parts of Vpu reduced HIV-1 infectious titres up to 30 times 
compared to wild type HIV-1, suggesting that the increase of the protein size may 
impede virus production [207]. Vpr has also been suggested to interact with cyclophilin 
A (CypA), a cellular protein implicated in the permissivity of cells to HIV-1 infection 
(see 1.9.) [208]. It is possible that Vpr packaging into virions influences CypA 
packaging or vice versa but this has yet to be investigated. 
Vpr expression leads to a G2 cell cycle arrest possibly by activating the G2 checkpoint 
ATM and Rad3-related kinase (ATR) (FIG 17) [209]. The physiological relevance of a 
cell cycle arrest has been suggested by the isolation of CA/p24+ CD4+ T-cells which 
were increased by up to 4-fold in a G2 arrested state with a tetraploid genome compared 
to CA/p24 negative CD4+ T-cells [210]. Studies trying to understand why HIV-1 
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manipulates the cell cycle showed that arresting cell division in G2 leads to an optimal 
HIV-1 LTR promoter activity and transcription [211]. Moreover, cell cycle arrest has 
been suggested to promote early steps of HIV-1 infection [212].       
Furthermore, Vpr has recently been demonstrated to recruit a cullin-RING ubiquitin 
ligase, more precisely cullin4A-DDB1 [213, 214]. Vpr interaction with DDB1 is 
mediated via the receptor protein DCAF1, and siRNA mediated silencing of DCAF1 
impairs the Vpr induced G2 cell cycle arrest [213]. Vpr binding to cullin4A-DDB1 
seems to increase the activity of this E3 ligase [214]. Interestingly, DCAF1 was 
identified in a genome wide siRNA screen as an important factor for Vpr deficient 
HIV-1 infection [105]. Bringing these findings together a model suggests that Vpr 
enhances the activity of cullin4A-DDB1 to an unknown cellular substrate by forming a 
cullin4A-DDB1-DCAF1-Vpr complex, causing the cell cycle arrest [215]. A proposed 
alternative model is the recruitment of a cellular host factor by Vpr, causing its 
ubiquitination by the cullin4A-DDB1 complex and degradation via the proteasomal 
pathway (FIG 17) [216]. To distinguish between these two possibilities, it would be 
interesting to investigate whether the fusion of heterologous E3 ubiquitin ligases to Vpr 
would also lead to the degradation of the proposed factor(s) and a G2 cell cycle arrest.  
 
1.6.2. HIV-1 Nef regulates the levels of cell surface proteins  
The HIV-1 negative factor, Nef, is a multifunctional 206 amino acid long protein (FIG 
2) that is associated with the cytosolic site of plasma membranes via an N-terminal 
myristyl anchor. Nef is conserved across diverse primate lentiviruses including SIVs 
and HIV-2 and is expressed very shortly after infection in a Rev independent manner. 
Despite its name, Nef has positive effects on HIV-1 replication (FIG 17).  
The first evidences that Nef modulates the pathogenicity of an infection in vivo came 
from experiments in which rhesus macaques were infected with a Nef deleted 
SIVmac239 [217]. The infected macaques showed higher CD4+ T-cell counts and none 
out of six SIVmac∆Nef infected animals died, whereas three out of seven animals 
infected with wild type virus died. Sequencing HIV-1 isolates from blood transfusion 
recipients that had been infected but remained free of AIDS symptoms for up to 14 
years, revealed deletions in the Nef coding region, demonstrating an impact of Nef on 
the progression of HIV-1 infected individuals towards AIDS [218].  
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An interesting ability of Nef is to down-modulate surface expression of diverse plasma 
membrane proteins including major histocompatibility complexes (MHC) class I and II, 
CCR5, CXCR4, CD4 and T-cell receptor (TCR-CD3) [219]. The down-modulation of 
surface levels of CD4 ensures efficient virus production, likely due to preventing 
interference of CD4 with gp120/ gp41 incorporation into budding virions [220, 221]. 
Nef binds the cytoplasmic tail of CD4 and recruits the clathrin adaptor protein complex 
2 (AP-2), which leads to the formation of clathrin coated pits, internalisation and 
lysosomal degradation of CD4 [222].  
Virus mediated decrease of MHC levels is a way to counteract the host immune system. 
In the presence of Nef, MHCs loaded with viral antigens are less efficiently presented at 
the cell surface, therefore cytotoxic T-lymphocytes (CTLs) are less efficiently activated 
ultimately benefiting the virus. However, since defined CTL escape mutations arise 
during HIV-1 infection in Gag, Tat and also Nef, the Nef impact on MHC presentation 
is not complete [223]. In contrast to downregulation of cell surface CD4 levels, Nef can 
decrease MHC levels by two different mechanisms: I) by interfering with their transport 
from the trans-Golgi network to the cell surface through recruitment of AP-1 complexes 
which direct them to endosomes [224] or II) by inducing a signalling cascade that 
ultimately leads to the endocytosis of cell surface MHC complexes [225]. 
Recent data suggests that Nef proteins from certain SIVs may also be able to counteract 
the antiviral protein tetherin, maybe through a similar mechanism as seen for CD4 cell 
surface downregulation (FIG 17) [194].  
Nef also interacts with the cytoplasmic tail of the TCR-CD3 complex, decreasing the 
TCR-CD3 signalling in infected T-cells. This probably occurs via interaction with the 
CD3 ζ chain causing the inhibition of T-cell activation by blocking N-Wasp mediated 
Pak-2 signalling [226] as well as decreased clustering of the kinase Lck and TCR in 
immunological synapses [227]. HIV-1 Nef however does not change the overall levels 
of TCR-CD3 at the cell surface. This stands in contrast to Nef alleles from less 
pathogenic HIV-2 and most SIVs, suggesting that the disfunction of efficient TCR-CD3 
downregulation by HIV-1 Nef may contribute to an increased pathogenicity [228]. 
Like Vpr, Nef is incorporated into virions [229]. Nef deleted virus is attenuated and this 
may depend on the route of infection of the target cell. VSV-G pseudotyped ∆Nef virus 
is similarly infectious as wild type virus [230]. In contrast, ∆Nef virus is attenuated 
when the virions harbour HIV-1 Env or amphotropic Env from MLV. Furthermore, the 
infectivity of ∆Nef virus can be rescued when Nef is provided in trans in virus producer 
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cells, but not in target cells [231]. Recently, Vpr’s characteristic of being packaged was 
exploited to analyse whether Nef incorporation is sufficient for rendering virus particles 
infectious [232]. The data showed that a fusion protein between Vpr and Nef with a 
central protease cleavage site was incorporated into virions and efficiently cleaved. 
However, resulting viruses were as attenuated as the ∆Nef virus [232]. This suggests 
that Nef acts during the assembly of virions or that the generated Nef was not 
functional. Recent work also proposes that dynamin-2 and clathrin are involved in the 
effect of Nef to enhance infectivity of virions [198]. The authors show that Nef binds to 
dynamin-2 and enhances infectivity of released virions. Inhibition of dynamin-2 by 
dominant negative versions specifically inhibited the Nef effect in an Env dependent 
manner as described above.  
 
1.6.3. HIV-1 Vif counteracts APOBEC3 proteins 
The HIV-1 virion infectivity factor (Vif) is a 192 amino acid long protein that has been 
known for a long time to influence the infectivity of HIV-1. Deletion of the vif gene 
rendered HIV-1 non-infectious in some cells (e.g. HUT78, CEM), whereas no 
infectivity was lost in others (e.g. SupT1, CEM-SS). In a series of elegant experiments 
Sheehy and colleagues demonstrated that human APOBEC3G is necessary and 
sufficient to inhibit HIV-1 in the absence of the viral vif gene when expressed in 
permissive CEM-SS cells [196]. APOBEC3G (A3G) is a member of the apolipoprotein 
B mRNA-editing catalytic polypeptide 1-like protein 3 (APOBEC3) protein family. In 
addition to A3G, A3F can block Vif deficient virus and is also counteracted by the 
HIV-1 Vif protein in a similar way to A3G [233]. Furthermore, human A3B, rat A1 and 
murine A3 are able to inhibit HIV-1 but are insensitive to HIV-1 Vif [234]. Despite the 
fact that HIV-1 encodes a countermeasure, A3G may impact on the clinical progression 
of HIV-1 infection towards AIDS [235]. This may be due to different expression levels 
of A3G between individuals infected with HIV-1, or due to differential expression 
levels in cell subsets within an individual. Indeed, a recent study suggests that 
CD4+Th1 cells have higher levels of A3G than CD4+Th2 and virions derived from 
CD4+Th2 cells are more infectious [236]. CD4+Th1 cells develop from naive T-cells in 
an environment of high levels of interferon alpha (IFN-α) and themselves secrete 
interferon gamma (IFN-γ). Although it has been controversial, evidence that A3G is 
upregulated by both IFN-α and IFN-γ has recently increased [237]. 
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A3G is packaged into virions in the absence of the viral Vif protein and causes its 
inhibitory effect on virus replication after the infection of a target cell (FIG 17) [238]. 
However, how A3G is packaged into the virions in the absence of Vif is unknown. 
Currently, Vif’s function seems to be solely to inhibit members of the APOBEC3 
family. A proposed mechanism of the antiviral activity of A3G, is the induction of 
deleterious hypermutations in the viral genome, a result of DNA cytidine-deamination 
on the minus strand during reverse transcription [238, 239]. A3G has two canonical 
cytidine deaminase domains (CDA), however only the C-terminal CDA mediates 
deamination [240]. In single stranded DNA, A3G deaminates cytidine (C) to uracil (U). 
Since the majority of single stranded viral DNA during reverse transcription is of 
negative polarity, C to U mutations result in guanosine (G) to adenosine (A) mutations 
in the plus strand.  Uracil residues are excised by uracil DNA glycosylases and replaced 
with thymidine (T). In some positions on the viral genome like the PPT or the LTR 
regions, where plus stranded DNA is single stranded during reverse transcription, C to T 
mutations are also frequently observed [241].  
 
 
 
FIG 18 Antiviral activity of APOBEC3G/F in the retroviral life cycle  
A) APOBEC3G and APOBEC3F (A3G/F) are counteracted by the HIV-1 Vif protein, preventing 
incorporation of A3G/F. Virus lacking Vif incorporates A3G/F which exerts its antiviral effect in the 
infected target cell by two mechanisms I) inducing hypermutations due to its cytidine deaminase of single 
stranded DNA and II) by interfering with elongation of reverse transcription, thereby reducing viral 
cDNA levels. Figure adapted from [242]. 
 
 
Although the editing activity of A3G has been suggested to play a role in restricting 
retroviral infection, recently it has become evident that A3G’s and A3F’s antiviral 
effects do not entirely depend on it. Newman et al. discovered that A3G mutants that 
have lost editing activity were still able to potently inhibit viral infectivity [243]. 
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Moreover, a rescue of the A3G mediated reduction in cDNA could not be observed in 
cells with inhibited or absent uracil DNA glycosylases UNG2 or SMUG1, suggesting 
that these enzymes are not necessary for A3G’s antiviral effect [244, 245]. A3G 
oligomerises in a RNA-dependent manner, suggesting that A3G might be packaged by 
interaction with the viral RNA [240]. A3G has been proposed to interfere with diverse 
steps during the process of reverse transcription, including tRNA annealing and priming 
of RT [246, 247], minus and plus strand transfer [248], and also provirus formation by 
interaction with IN [249] (FIG 7). A recent study demonstrated that an important 
mechanism for the hypermutation independent activity of A3G is likely to be its 
interference with reverse transcription elongation [195]. In this model A3G bound to 
viral RNA sterically hinders reverse transcriptase, inhibiting efficient cDNA synthesis. 
Using different primer/ probe sets in a quantitative PCR to detect viral cDNAs of 
different lengths, the study showed that the effect of A3G increases with increasing 
length of cDNA [195]. This suggests that A3G bound to viral RNA may interfere with 
cDNA elongation (FIG 18BII). 
HIV-1 Vif prevents the incorporation of A3G into virions by recruitment of the 
cullin5-elonginB/C ubiquitin ligase complex [250]. The recruitment of an as far 
unknown E2 ligase via cullin5 consequently leads to ubiquitination of A3G and 
degradation by the proteasome so that produced virions are free of A3G [251, 252]. 
However, a recent study suggests that A3G ubiquitination is not necessary for a Vif-
dependent degradation by the proteasome, suggesting that other factors in the complex, 
possibly Vif itself, may be a target for ubiquitination causing degradation of the whole 
complex [253]. The ability of Vif to counteract A3G is dependent on the 
phosphorylation status of serine residue 144 in the suppressor of cytokine signalling 
(SOCS)-box of Vif, which interacts with elongin C and thereby promotes cullin5 
recruitment. Phosphorylation at this residue reduces its interaction with elongin C and 
consequently decreases degradation of the complex and anti-A3G activity [254]. 
Phosphorylation of Vif has been long known to influence its ability to enhance HIV-1 
infectivity. Yang et al. demonstrated in 1996 that Vif is phosphorylated and showed two 
years later that the mitogen activated protein kinase (MAPK) phosphorylates Vif at 
residue S144 [255, 256]. Interestingly, a recent study showed that Vif interaction with 
A3G is strengthened by protein kinase A (PKA) mediated phosphorylation of A3G 
residue T32 [257]. Studies performed before the discovery of A3G showed, that Hck, a 
tyrosine kinase from the Src family, was able to inhibit ∆Vif but not wild type HIV-1 
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and Vif was not the target of phosphorylation [258]. It would be interesting to 
investigate whether Hck is able to phosphorylate T32 in A3G.  
APOBEC’s sensitivity to Vif antagonism is species-specific. More precisely, human 
A3G cannot block wild type HIV-1, whereas A3G from e.g. African green monkeys 
(AGM) is able to block wild type HIV-1. Vice versa, SIVagm Vif is able to counteract 
AGM A3G, but not human A3G. Species-specificity is therefore a result of the inability 
of HIV-1 Vif to bind A3G of e.g. AGMs [259]. Interestingly, changing only one amino 
acid residue in human A3G to the residue found in AGM (D128K), disrupts interaction 
with HIV-1 Vif and confers the ability to bind SIVagm Vif, thereby switching 
species-specificity [260]. 
APOBEC proteins have been implicated as antiviral factors against other viruses 
including hepatitis B virus (HBV), adeno-associated virus (AAV), as well as against 
endogenous retrotranspositions of Alu segments. It is clear that the APOBEC family 
represents an important set of proteins to counter viral, in particular retroviral, infection 
and cross-species transmission.  
 
1.6.4. HIV-1 Vpu counteracts tetherin/ BST2/ CD317  
The HIV-1 unique viral protein Vpu is a ~16 kDa large type I transmembrane protein 
localised to the plasma membrane as well as intracellular membrane compartments. In 
the primate lentivirus lineage only HIV-1, SIVcpz and SIVgsn have Vpu proteins, 
whereas for example HIV-2 and SIVmac lack Vpu. Vpu is a viroporin and functions as 
a monovalent cation ion channel, although the importance of this function for the virus 
life cycle is not clear [261]. Vpu has an N-terminal transmembrane domain and a 
C-terminal cytoplasmic domain, which is a target for casein kinase II mediated 
phosphorylation [262]. Phosphorylation of the cytoplasmic domain is important for 
Vpu’s ability to downregulate CD4 expression, whereas it is not involved in the positive 
effect of Vpu on virus release [263]. Like Nef (see 1.6.2.), Vpu can decrease surface 
levels of CD4 by mediating its degradation [264]. However, unlike Nef, which induces 
lysosomal degradation of CD4, Vpu mediated degradation involves the ubiquitin-
conjugating and proteasomal pathway [265]. CD4 degradation is mediated via Vpu 
binding to the cytoplasmic tail of CD4 at the endoplasmic reticulum and the recruitment 
of two cellular factors, beta TrCP1 (and possibly TrCP2) and Skp1p, which form a 
1. INTRODUCTION 48
complex that initiates ubiquitination and degradation [266, 267]. However, the specific 
target for ubiquitination remains unknown. 
Augmentation of HIV-1 release in the presence of Vpu, and impaired virus release and 
accumulation of cell associated viral proteins in its absence, was observed early after 
identification of HIV-1 [268]. Moreover, it was soon realised that the positive effect is 
transferable to other retroviruses, suggesting that a cellular factor non-specifically 
repressed virus release in a retrovirus common pathway [269]. It was also shown that 
the protein targeted by Vpu, resided in the plasma membrane and prevented the release 
of nascent particles [270]. In addition, the effect of Vpu could be overcome by 
pretreating infected cells with interferon [271]. Together these observations led to the 
discovery of the antiviral activity of a protein known as bone marrow stromal factor 2 
(BST2) or CD317 [193, 272]. Due to its ability to inhibit HIV-1 release by tethering 
nascent virions to the plasma membrane, it is now also referred to as tetherin (FIG 17). 
Tetherin is a transmembrane protein with an N-terminal cytoplasmic domain, followed 
by a transmembrane helix, an extracellular alpha helical domain and a C-terminal 
glycosylphosphatidylinositol (GPI) anchor (FIG 19). It is heavily glycosylated at amino 
acid residues N-terminal of the extracellular alpha helical domain. Recent data suggests 
that N-terminal glycosylation may be dispensable for tetherin mediated restriction of 
virus release [273].  
Vpu may mediate tetherin degradation in a proteasome dependent manner [274, 275]. 
This was suggested to be cell type specific, since increased virus release by Vpu was 
observed without a decrease of cell associated tetherin in some cell lines, e.g. H9 [276]. 
However, since HIV-1 infectivity in these cells was only rescued by maximal 3-fold in 
the presence of Vpu, it is very likely that the loss of cell associated tetherin was below 
detectable levels. It is possible that Vpu causes tetherin degradation by recruitment of 
the beta TrCP1/Skp1p complex, followed by ubiquitination and proteasomal 
degradation, similarly to its effect on CD4. In addition, a recent study suggests the 
involvement of the endolysosomal pathway for Vpu mediated degradation of tetherin 
[277]. 
HIV-2 does not possess a Vpu protein but the HIV-2 envelope protein has been 
demonstrated to have Vpu like activity and to enhance viral budding [278, 279]. Indeed, 
a recent study suggests that HIV-2 Env is able to counteract tetherin [194]. Human 
tetherin also restricts MLV, however it is currently unknown whether murine tetherin 
restricts MLV and if so, how MLV counteracts tetherin restriction. In addition, the 
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unrelated Ebola virus is restricted by tetherin and counteracts the block with its 
envelope glycoprotein [271, 280]. For most viruses restricted by tetherin, the viral 
countermeasures remain unidentified. However, it was demonstrated that human 
tetherin restricts VSV-G pseudotyped VLP production of EIAV, FIV, SIVmac, 
SIVagmSab, Rous sarcoma virus (RSV), Mason Pfizer monkey virus (MPMV), a 
reconstituted human endogenous retrovirus (HERV-Kcon), human T-cell leukaemia 
virus (HTLV-I), as well as primate foamy virus (PFV) [281].  
Tetherin has been positively selected during primate evolution and acts in a 
species-specific way, e.g. Tantalus monkey tetherin is able to block HIV-1 virus release 
however is not counteracted by HIV-1 Vpu [274, 282]. Moreover, mouse, rat and rhesus 
macaque tetherins efficiently block HIV-1 and Vpu is also unable to rescue release 
[275, 282]. Positively selected tetherin residues are located close to or within tetherin’s 
transmembrane helix. A recent study suggests that tetherin residues L22 to I46 
constitute the alpha-helical transmembrane domain and that helix residues P40 and T45 
are critical for the sensitivity to HIV-1 Vpu [282]. Mutation of human tetherin residues 
P40 or T45 to residues found in Tantalus monkey tetherin, render the human protein 
insensitive for counteraction by HIV-1 Vpu [274, 282]. So far, the Vpu determinants for 
species-specificity have not been mapped. However, Vpu’s transmembrane region 
seems to be important. It would be interesting to compare Vpu proteins from closely 
related SIVcpz and HIV-1, which might reveal determinants of Vpu for tetherin 
counteraction. Most SIVs, including SIVmac, do not possess a Vpu protein. Recent data 
suggests that they counteract tetherin restriction with their Nef protein providing yet 
another way to escape innate immunity [194].   
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FIG 19 Tetherin restricts virus particle release and is counteracted by Vpu, HIV-2 Env and SIV Nef  
Tetherin functions to tether nascent virus particles to the plasma membrane causing their endosomal take 
up and degradation. Vpu is able to counteract tetherin possibly by β-TrCP mediated endolysosomal or 
proteasomal degradation. HIV-2 Env counteracts tetherin by an unknown mechanism. Nef proteins from 
SIVs may also counteract tetherin, however the mechanism is not known.   
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1.7. Fv1 restriction of MLV 
A subgroup of intrinsic factors includes molecules that act shortly after the retroviral 
capsid has entered the cytoplasm of a target cell. The mouse Friend virus 
susceptibility 1 (Fv1) gene encodes the prototypic restriction factor. It is an almost 
full-length endogenous retroviral Gag protein encoded by mice [188]. It is one of the 
genes controlling the susceptibility of mice to infection by murine leukaemia virus, 
originally described in the early 1970’s [283, 284]. Interestingly, Fv1 homologues are 
only found in mice, but not in rats, suggesting that the virus from which Fv1 derives 
infected mice after the divergence of Mus and Rattus.  In an extensive study Best and 
colleagues were able to identify two major alleles from AKR and C57BL/6 mice, Fv1N 
and Fv1B, respectively [188]. N tropic MLV (MLV-N) is restricted by Fv1B but not 
Fv1N, therefore infects AKR but not C57BL/6 or BALB/3T3 mice. MLV-B has the 
opposite phenotype. MLV-N and MLV-B differ in several amino acids, however 
switching CA amino acid residue 110 is sufficient to switch the tropism to Fv1 
restriction [285]. MLV-N with R110 substituted to the residue found in MLV-B (E110) 
loses sensitivity to Fv1B and gains sensitivity to Fv1N restriction [285]. In addition to a 
longer C-terminus, Fv1B differs from Fv1N in two internal positions 358 (E/K, 
Fv1B/Fv1N) and 399 (R/V, Fv1B/Fv1N) and all three differences are important for 
specificity for MLV-N or MLV-B restriction (FIG 20) [188, 286]. In addition, other 
alleles of Fv1 have been described. Naturally occurring MLV-N like viruses have been 
found that escape restriction by these alleles without changing CA residue R110 but due 
to changes at other CA positions suggesting that CA residue 110 is not solely 
determining tropism to Fv1 alleles [287]. MLV restricted by Fv1 completes viral DNA 
synthesis by reverse transcription but does not form a provirus (FIG 17) [288, 289]. In 
addition, viral DNA circles are reduced for Fv1 restricted MLV, suggesting that the 
block occurs before nuclear entry of PICs (FIG 17) [288, 289]. A deletion study by 
Bishop et al. clearly showed that the C- and N-terminus of Fv1 are important for 
restriction of MLV, whereas internal deletions had only minor effects on the restriction 
ability [290]. The crystal structure of Fv1 has not been published yet. However, 
biochemical investigation of Fv1 suggested that it consists of an N-terminal domain 
(residues K16 to R157), a central domain (residues 158 to 243) and a C-terminal 
domain (S244 to L440) (FIG 20) [291]. The N-terminal domain has a predicted coiled 
coil between residue 88 and 115, therefore possibly acts as a dimerisation domain, 
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whereas the carboxy-terminus presumably functions as the virus recognition domain 
and interacts with the MLV capsid [291]. The C-terminus also contains the major 
homology region of retroviral Gag proteins between residue 267 and 286 [292]. 
Mutation of the MHR abrogates restriction [290]. The details of the molecular 
mechanism underlying restriction by Fv1 are unclear, but current data suggest that 
retroviral capsids interact early after entry with Fv1 rendering them non-infectious 
[293].  
Interestingly, a block to viral infection in certain primate and human cell lines to MLV 
infection was described, which was similar to the Fv1 phenotype in murine cells, 
despite the lack of an Fv1-like gene in those cell lines [294, 295]. Experimental analysis 
of that observation led to the discovery of the alpha isoform of the cytoplasmic body 
component tripartite motif protein 5 (TRIM5α) as a potent antiretroviral protein 
(see 1.8.) [184, 296-298]. TRIM5α blocks viral infection early after virus entry and in 
most cases, unlike Fv1, by inhibition of viral DNA synthesis (FIG 17) [184]. When 
TRIM5α and Fv1 are expressed together, both restriction factors compete for binding to 
incoming viral cores however the actual restriction mechanism occurs late for Fv1 and 
early for TRIM5α, as judged by levels of viral DNA reverse transcription products 
[293]. Despite the differences in the stage of the block to viral infection, some aspects 
of MLV restriction by Fv1 are similar to restriction by TRIM5α. Like TRIM5α, Fv1 is 
saturable and both factors target the incoming viral CA protein. The block of MLV-N 
by both, Fv1N and human TRIM5α, depends on R110 in the MLV CA protein [285, 
294, 299, 300]. In addition, both molecules are believed to form cytoplasmic dimers 
consisting of a C-terminal virus binding moiety and an N-terminal domain, which may 
be involved in dimerisation [291, 301]. Like TRIM5α, Fv1 seems to be positively 
selected, suggesting that it is under selection pressure from MLVs in mice [302-305]. 
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FIG 20 Schematic protein organisation of Fv1N and Fv1B 
Figure shows Fv1B (top) and Fv1N (bottom) domain organisation. NTD, N-terminal domain; CD, central 
domain; CTD, C-terminal domain; MHR, major homology region. Predicted N-terminal alpha helical 
domain is indicated.  
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1.8. TRIM5α 
TRIM5α was first isolated in 2004 from a rhesus macaque cell line and shown to block 
HIV-1 infection of old world monkey cells [184].  
As a typical TRIM protein, the alpha splice form of TRIM5 is comprised of a RING, B-
box, coiled-coil domain and a C-terminal B30.2 or PRY-SPRY domain. The latter 
harbours the major virus recognition determinants [306-309], with which dimeric 
TRIM5α complexes bind to incoming retroviral capsids. An early study on the 
oligomerisation proposed that TRIM5α oligomerises as homotrimers [310]. However, 
more recent in vitro biochemical assays with recombinant TRIM5α suggest that it forms 
homodimers and that dimeric B30.2 structures bind viral CA structures [301]. TRIM5 is 
alternatively spliced into different isoforms of which only the alpha isoform has an 
antiviral activity due to its virus binding B30.2 domain. Shorter TRIM5 isoforms β, γ, 
δ and ε have been described (FIG 21) [311]. Isoforms δ and γ, which both lack the 
B30.2 domain, have been shown to interfere with restriction presumably due to the 
disruption of homodimeric TRIM5α complexes or saturation of co-factors [184, 293].  
Like many other TRIM proteins, TRIM5α is interferon inducible supporting its 
important function as a restriction factor [312-314]. In contrast to restriction by Fv1, 
most TRIM5α proteins block virus infection before reverse transcription is complete 
(FIG 17) [184]. However, the block to RT can be largely abrogated by chemical 
inhibition of the proteasome [315]. Formation of 2-long terminal repeat (2-LTR) circles 
and infection cannot be rescued by proteasome inhibition [316]. The role of the RING, 
B-box 2 and coiled-coil domains in the antiviral function of TRIM5α remain largely 
unclear but mutation studies indicate that all three domains are important for full 
antiviral function of TRIM5α [317-321]. In addition to an early block after virus entry, 
rhesus macaque TRIM5α has been proposed to interfere with HIV-1 particle production 
(FIG 17). However, this role remains controversial and contradicting results have been 
published [201, 202]. 
TRIM5α belongs to the large family of TRIM proteins with diverse functions. Despite 
many functional differences TRIM proteins have common features. The most obvious 
shared characteristic between TRIM proteins is the RBCC or tripartite motif consisting 
of three characteristic domains, the RING, the B-box and the coiled coil domain. The 
order of the three domains and the spacing between the individual domains is highly 
conserved between TRIM family members.   
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FIG 21 TRIM5 splice isoforms  
The human TRIM5 gene is shown and the different splice isoforms TRIM5α, δ, γ and ε are indicated. 
Figure adapted from [322]. 
 
1.8.1. The RING domain 
The really interesting new gene (RING) domain is common to TRIM proteins and is the 
most amino-terminal domain of the tripartite motif. The length and the start of the 
RING domain after the methionine start codon varies between TRIM proteins [323]. 
The RING domain is a zinc finger motif defined by the consensus sequence 
CX2CX(9-39)CX(1-3)HX(2-3)C/HX2CX(4-48)CX2C  in which the histidine (H) and cysteine 
(C) residues indicated in red coordinate in total two zinc ions [324]. The structure of the 
human TRIM5 RING domain has been solved and is depicted in FIG 22A. Initially, the 
RING domain was shown to possess a E3 ubiquitin-ligase activity in TRIM5δ, a C-
terminally truncated isoform that associates with the topoisomerase-I interacting 
proteins BTBD1 and BTBD2 [325]. A recent study showed that also human TRIM5α 
possesses an E3 ubiquitin-ligase activity and in addition to self-ubiquitination can also 
be ubiquitinated by TRIM21 in vitro [326]. The function of the RING domain in 
TRIM5α restriction is unclear and is a subject of this study (see 5.2.). 
RING domains of many TRIM family members including TRIM5, TRIM11, TRIM21, 
TRIM22 and TRIM25 have been demonstrated to have E3 ubiquitin-ligase activity 
[326-330]. In addition to E3 ubiquitin ligase activity some TRIMs may also have an E3 
small ubiquitin-related modifier (SUMO) ligase activity. In particular, TRIM19 and 
TRIM63 have been described to bind to SUMO-conjugating E2 enzyme Ubc9 [331, 
332]. In addition, TRIM27 interacts with the SUMO conjugating ligase PIAS [333]. 
TRIM25, also known as estrogen-responsive finger protein (EFP), is able to mediate the 
transfer of yet another ubiquitin-like protein called ISG-15 [334]. Mutation of the 
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TRIM25 RING domain led to a diminished ISGylation of its target protein 14-3-3σ 
indicating the importance of the RING domain in this reaction [334].  
Evidence for functional importance of the RING domain in TRIM proteins are provided 
by the observations that RING deletion mutants may have aberrant subcellular 
localisations compared to wild type proteins, as seen for example for TRIM6 and 
TRIM8 [311]. In addition, mutation of the cysteines involved in zinc-coordination often 
abolishes TRIM protein function. This was, for example, observed for murine TRIM30 
mediated degradation of TAB2 [335]. Mutation of cysteine C15A in human or rhesus 
macaque TRIM5α resulted in the loss of self-ubiquitination and significantly decreased 
antiviral activities [184, 326].  
However, the function of some TRIM proteins does not entirely depend on an intact 
RING domain. A deletion study on TRIM27 for example demonstrated that the RING 
and B-box domains are dispensable for the effect on inhibiting NF-κB activity and IRF3 
nuclear translocation [336]. Moreover, some TRIM family members do not possess a 
RING domain however their remaining domain organisation resembles that of other 
TRIM proteins justifying a classification within the family. For example TRIM14, 
TRIM16, TRIM20, TRIM29, TRIM44 and TRIM66 lack a RING domain however all 
of them contain at least one B-box domain [311, 322]. 
 
1.8.2. The B-box domain 
B-box domains are found in almost all TRIM family members. Two different types of 
B-box domains, B-box1 and B-box2, can be distinguished according to their consensus 
sequences. Interestingly, a B-box2 domain will always follow a B-box1 domain, and 
only B-box2 domains are found alone, suggesting that B-box1 domains may have 
evolved from B-box2 domains. Using bioinformatic and biochemical approaches, a 
recent study suggests an importance of the ~30-48 amino acid residues long region 
located between the RING domain and the first B-box domain, which has been 
misleadingly called RING-B-box-Linker (RBL) region [337]. The study identified this 
region to be unique to TRIM proteins and showed that both, the RING domain and the 
RBL alpha helix are mutually dependent on each other with regards to zinc-coordination 
and helix formation. This strengthens the notion that the RBCC motif is conserved in its 
domain organisation and spacing, and that the domains act as a single unit. Like RING 
domains, B-box domains also coordinate zinc and have a similar ternary structure to 
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RING domains, suggesting that they may share similar functions and may have evolved 
from a common ancestral domain [338]. Information on the function of B-box domains 
are limited and mainly come from deletion or mutation studies. Deletion of the B-box2 
domain in TRIM6 or TRIM29, for example led to an aberrant subcellular localisation 
compared to the wild type proteins and to a loss of self-association, in case of TRIM29 
[311]. However, these observations are likely to be artefacts of perturbed protein 
folding.  
The structure of the human TRIM5 B-box domain is depicted in FIG 22B. The B-box 
domain is a B-box of type 2, consists of three antiparallel β-sheets and, like the TRIM5 
RING domain, coordinates two zinc ions. The function of the B-box domain of TRIM5 
is unclear however a similar structure to the RING domain may suggest redundant 
functions. Moreover, an intact B-box is important for TRIM5α’s antiviral activity. The 
function of the TRIM5α B-box domain in the restriction mechanism is the subject of 
this study (see 5.2.1.).  
 
  
FIG 22 Structures of the human TRIM5 RING and B-box domains.  
RING domain residues M1-E78 (A) and B-box residues S86-F129 (B) are shown. RING α-helix from 
Q36-K45 is shown as a green tube. Antiparallel β-sheets between L103-I113 and H126-F129 in the B-box 
are shown as brown arrows. (Entrez structure PDB IDs: RING, 2ECV; B-box, 2YRG; pictures derived 
using Cn3D4.1)  
 
1.8.3. The coiled coil domain 
The coiled coil domain of TRIM proteins is important for oligomerisation of monomers, 
which in case of TRIM5α most likely results in dimers [301, 339]. Interestingly, despite 
the large number of TRIM family members the majority of TRIM proteins form 
A B 
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homomultimers and only a few have been described to form heteromultimers, including 
TRIM1, TRIM18, TRIM19, TRIM24, TRIM27, TRIM29 and TRIM31 [311]. TRIM 
proteins have defined subcellular localisations and the correct localisation depends on 
the coiled coil domain since deletion of the domain often results in a diffuse distribution 
of the protein within the cell [311]. The coiled coil domain is found in almost every 
TRIM protein. However, some members, in particular TRIM48, TRIM49, TRIM52, 
TRIM53 and TRIM61 have no predicted coiled coil structures, suggesting that they may 
act as monomers [340]. 
Analysis of the secondary structure of the TRIM5α coiled coil domain by computer 
based prediction suggested that two separate regions, which both form coiled coils, are 
linked by a spacer region. Mutational analysis of the three regions showed that all three 
regions contribute to oligomerisation of TRIM5α molecules, however mutations in the 
more carboxy-terminal coiled coil were more deleterious to the ability of the protein to 
restrict than mutations in the amino-terminal part [341].  
In contrast to owl monkey TRIMCyp, the rhesus TRIM5 coiled coil domain could be 
substituted by coiled coil domains of other TRIMs without significantly affecting the 
antiviral activity [341].  This result seems rather surprising given the fact that many 
TRIMs have been described to be able to restrict HIV-1 when fused to the owl monkey 
TRIMCyp CypA domain [342]. It suggests different functional requirements for the 
coiled coil domain between TRIMCyp and rhesus TRIM5α. In fact, HIV-1 infection 
restricted by TRIMCyp was more readily rescued by expression of coiled coil domains 
from e.g. TRIM27 than HIV-1 restricted by rhesus TRIM5α [341]. In addition, 
expression of the owl monkey TRIMCyp coiled coil domain rescued infection of HIV-1 
in owl monkey kidney cells [343]. Expression of the rhesus TRIM5α coiled coil domain 
in rhesus TRIM5α expressing cells also rescued infectivity of HIV-1 [341]. Yeast-two 
hybrid assays also showed that the human TRIM5α coiled coil domain alone is able to 
bind to full-length human TRIM5α [344]. In conclusion, the TRIM5α coiled coil 
domain is important for dimerisation of TRIM5α and for its function as a restriction 
factor. 
1.8.4. The B30.2 domain 
Domains that are located C-terminal to the tripartite motif differ dramatically in their 
sequences between different TRIM proteins (FIG 24). Although some TRIM proteins 
remain unclassified, most family members have been grouped into 11 sub-families 
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according to their domain organisation [323, 340]. The biggest class (C-IV) contains 
members that possess a PRY-SPRY motif. In many cases it is thought that the 
C-terminal domain acts as a binding domain, which recruits the RBCC motif to exert its 
enzymatic function on a certain protein that is targeted by the C-terminal domain. 
TRIM5α also possesses a B30.2 or PRY-SPRY domain, which was shown to bind to 
retroviral capsids (FIG 24).  
In addition to B30.2 domains, further C-terminal domains that can be found in TRIM 
proteins include fibronectin type III motifs, plant homeodomains (PHD), BROMO 
domains, transmembrane domains, filamin-type immunoglobulin domains, NHL (first 
characterised in proteins NCL-1, HT2A and Lin-41) repeat motifs, meprin and TRAF 
homology (MATH) domains and ADP-ribosylation factor (ARF) domains. The 
C-terminus can provide clues for the function of the TRIM protein. For example 
TRIM28 possesses a BROMO domain, which is known to interact specifically with 
acetylated lysines. BROMO domain containing proteins are associated with chromatin 
and histone acetyltransferases. Indeed, TRIM28 was recently found to mediate provirus 
silencing of retroviruses in embryonic stem cells by binding to ZFP809, a protein that 
associates with the primer binding site of integrated retroviral DNA (FIG 17) [190, 
345]. The importance of the enzymatic activity of the TRIM28 RBCC in this process 
has to be investigated.  
The structure of the TRIM5α B30.2 domain has not yet been solved. Recently however, 
the PRY-SPRY structures of the Drosophila melanogaster protein GUSTAVUS and 
human TRIM21 were solved and show important features of the PRY-SPRY domain 
(FIG 23) [346, 347]. The B30.2 domain consists of beta sheets building the core and 
variable loops which extrude and form the surface of the domain (FIG 23). 
The TRIM5α B30.2 domain harbours the determinants for recognition of the viral 
capsid (FIG 23) [184]. Not surprisingly, TRIM5α proteins from different species vary 
mostly in their B30.2 domains, in particular in four variable regions (v1-v4) (FIG 35), 
which differ in sequence and length, strongly suggesting that these represent the regions 
of interaction with viral capsids [348]. Using chimaeric proteins between human and 
rhesus TRIM5α, it was shown that v1 and v3 are important for MLV-N restriction by 
human TRIM5α [306]. In a similar but more complex study it was demonstrated that v1, 
v2 and v3 contribute to the binding specificity of the B30.2 domains of primate 
TRIM5α molecules to different viruses [308]. Changing 9 amino acid residues in the 
human TRIM5α B30.2 v1 region to the corresponding residues found in rhesus TRIM5α 
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allows this chimaeric protein to restrict HIV-1 potently by up to 10-fold [307]. 
Interestingly, changing a single arginine residue (R332) in the human TRIM5α B30.2 
v1 region to proline found in rhesus TRIM5α (P332) has been shown to increase 
restriction of HIV-1, however the antiviral activity is weaker than that of the 9 amino 
acid substitution mutant [349]. A single amino acid change cannot only change but also 
can expand TRIM5α restriction specificity to other viruses. This has been demonstrated 
by mutating human TRIM5α B30.2 residue Y336, expanding its restriction to MLV-B 
and NB-tropic MLV [350]. Comparing Old World and New World primate B30.2 
domain sequences, large differences in the variable regions can be detected. TRIM5α 
proteins from different African green monkeys (agm) have a 20 amino acid long 
duplicated sequence in v1, whereas the spider monkey TRIM5α shows a triplicated 
sequence in its v3 region suggesting a tremendous evolutionary pressure on these 
domains [348]. In addition, it was shown that the duplication found in agm TRIM5α is 
important for the restriction specificity of this protein [351]. 
Throughout primate evolution the B30.2 domain has changed significantly at these 
specific sites that interact with retroviral capsids, supporting the theory of co-evolution 
of host and retroviruses. This strong positive selection led to species-specific TRIM5α 
molecules restricting different retroviruses [303, 352, 353]. The virus that is found 
naturally in a host has escaped restriction by changing its CA sequence in a way that the 
host TRIM5α cannot recognise it. Rhesus TRIM5α for example is able to strongly block 
infection by HIV-1, whereas its human homologue only inhibits HIV-1 weakly [184]. In 
addition to interspecies variation, TRIM5α from rhesus macaques is also under strong 
selection within the species [352]. In contrast to human TRIM5α, multiple 
polymorphisms have been found in the rhesus macaque TRIM5α B30.2 domain, which 
affect restriction specificity of diverse retroviruses [352, 354, 355].  
 
            
FIG 23 Structural organisation of the PRY-SPRY domain 
A simplified cartoon structure is shown. The core of the domain consists of two sheets (sheet A and B), 
which are built of anti- parallel beta sheets (green and orange). Variable loops extrude and build different 
surfaces that can interact with target proteins. In TRIM5α surface exposed variable loops contain the 
species-specificity determinants for TRIM5α restriction and interact with retroviral capsids. Figure 
derived from [347]. 
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FIG 24 Sub-families of TRIM proteins 
Tripartite motif (TRIM) proteins are grouped into 11 classes C-I to 
C-XI and some unclassified members (not depicted). The biggest class 
contains members that possess a PRY-SPRY C-terminal domain 
(C-IV). Proteins known to be involved in the antiviral response are 
indicated with an asterisk. TRIM proteins known to be upregulated by 
interferon are highlighted in red boxes. Most proteins known to be 
involved in antiviral or immune modulatory processes are found in 
C-IV. Scale is amino acid numbers. Figure adapted from [323]. 
* 
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1.8.5. Characteristics of TRIM5 expression 
TRIM5α forms discrete concentrations in the cytoplasm, referred to as cytoplasmic 
bodies [184]. These may in some cases be aggresomes, which are thought to immobilise 
intracellular protein accumulations, rendering them susceptible to proteasomal 
degradation [356]. However, these subcellular structures have only been observed for 
exogenously expressed, tagged TRIM5α proteins and it was shown that pre-existing 
cytoplasmic bodies are not essential for TRIM5α restriction [357]. It is not clear 
whether endogenously expressed TRIM5α also forms cytoplasmic bodies since 
available TRIM5α antibodies are inefficient at detecting endogenous TRIM5α. The 
formation of cytoplasmic bodies likely depends on the concentration of the protein 
within the cytoplasm, which is also increased by stimulation with interferons [312, 358]. 
In addition to cytoplasmic bodies, TRIM5α is also found diffusely in the cytoplasm and 
it has been demonstrated that TRIM5α exchanges between cytoplasmic bodies and the 
diffuse pool constantly [359]. Interestingly, it has been shown that HIV-1 associates 
with cytoplasmic TRIM5α bodies after infection and that proteasome inhibition leads to 
the aggregation of HIV-1 viral complexes in these bodies and no loss of detectable viral 
capsids [360]. Aggresomes form also as an effect of autophagy and virus replication has 
been associated with autophagy induced aggresomes called autophagolysosomes [361]. 
In addition, autophagy induced aggresomes have been suggested to be involved in 
protecting cells from virus infection by mediating MHC class II presentation of viral 
antigens [362]. However, formation of TRIM5α aggresomes and restriction of virus 
infection by TRIM5α have not yet been linked to autophagy. It is possible however, that 
the block to infection after proteasome inhibition is caused by protein aggregation and 
autophagy of accumulated virus-restriction factor complexes. It might therefore be also 
an interesting hypothesis that restriction by TRIM5α may enhance MHC class II antigen 
presentation but this has yet to be investigated. 
Microarray expression analyses comparing different tissues (GNF Expression Atlas 2 
Data from U133A and GNF1H Chips; http://genome.ucsc.edu) demonstrated that 
human TRIM5α is proportionally more expressed in peripheral blood lymphoid cells 
like dendritic cells, monocytes, natural killer cells, CD8+ T-cells and CD19+ B-cells 
suggesting that it may have a protective role against retroviral infection of immune 
cells. However, since expression of TRIM5α is IFN inducible the array data may not 
reflect the situation after virus infection.   
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1.8.6. Other TRIM family members and their roles in innate immunity 
The TRIM protein family is heterogenous and large, comprising 65 and 64 members in 
humans and mice, respectively (FIG 24) [322, 323]. Interestingly, worms and flies 
possess only ~20 and ~10 members, which indicates how the family has expanded 
during evolution [323]. Members of the TRIM family obtain diverse functions in a wide 
range of biological processes and many of them are associated with pathways of innate 
immunity often against viral infections. TRIM19 (also known as promyelocytic 
leukaemia protein, PML) for example is able to block herpes simplex virus (HSV) 
infection [363], may interfere with Adenovirus [364] and cytomegalovirus infection 
[365], may be targeted by the Epstein-Barr virus nuclear antigen 1 (EBNA1) protein 
[366] and has been suggested to mediate antiviral mechanisms against RNA viruses like 
poliovirus [367], Ebola virus [368], Lassa virus [369], Rabies virus [370] and influenza 
[371]. Furthermore, it has been proposed to exert an antiviral activity against HIV-1 at a 
step prior to nuclear translocation of the pre-integration complex [372], as well as 
against human foamy virus (HFV) by sequestering the transcriptional transactivator 
protein Tas and repressing transcription [373]. However, the biological relevance of the 
results obtained from most of these studies remains unclear.  
Murine leukaemia virus (MLV) replication is restricted in embryonic stem cells by 
TRIM28 which mediates transcriptional silencing of the provirus by binding to the 
MLV primer-binding site (PBS) [190]. TRIM22 has been suggested to have 
antiretroviral activity and was shown to decrease HIV-1 production by approximately 
4-fold in a human osteogenic sarcoma (HOS) cell line expressing CD4 and CXCR-4 
[200, 374]. By using siRNA mediated knock down and exogenous expression 
experiments a recent study investigated a large group of TRIM family members for 
antiviral activities and showed that human TRIM11 and TRIM15 can inhibit HIV-1 and 
MLV virus release by 4- and 5-fold, respectively [199]. However, since these effects are 
small, the physiological relevance remains controversial. 
In addition to a direct effect on virus replication TRIM family members can exert their 
effect indirectly through the regulation of interferon (IFN) induced signalling pathways 
or pathogen recognition pathways involved in the activation of nuclear factor κB 
(NF-κB) leading to the synthesis of IFN and other cytokines. Type-I IFNs (IFN-α and 
IFN-β) are produced by many cell types in response to viral infections. In contrast, 
type-II IFN (IFN-γ) is only synthesised by T-cells and natural killer cells. The released 
IFNs act to induce an antiviral state in cells by binding to its receptors and inducing 
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signalling cascades that increase the expression of many antiviral proteins. Expression 
of many TRIM proteins is changed in response to IFNs, suggesting that they may be 
involved in antiviral processes. TRIM family members that are upregulated in response 
to IFN include TRIM5 [312-314], TRIM8 [375], TRIM19 [376], TRIM21 [377], 
TRIM22 [378] and TRIM25 [314, 334]. Moreover, a recent study showed that gene 
expression of 27 of the 72 human TRIM proteins is sensitive to IFN type I or II 
treatment in primary blood lymphocytes or monocyte derived macrophages [340]. The 
upregulated TRIM proteins are shown in FIG 24. In addition, this study revealed that 
some TRIM proteins, in particular TRIM9 and TRIM54, are specifically upregulated in 
FcγR-activated macrophages, suggesting a role in the immune control of antibody 
opsonised pathogens. A study in mice showed that TRIM proteins are differentially 
expressed in macrophages, myeloid and plasmacytoid dendritic cells and in a CD4
+
 T-
cell subset in response to IFN suggesting that the function of TRIM proteins in innate 
immune control may vary in different immune cells [358].  
TRIM25 acts in concert with the retinoic-acid-inducible gene I (RIG-I) protein that 
recognises viral RNAs [379].  By binding to RIG-I’s first caspase-recruitment domain 
(CARD) via the PRY-SPRY domain, TRIM25 is able to ubiquitinate the second RIG-I 
CARD domain, which ultimately results in increased downstream signalling of RIG-I 
and IFN-β production and supports antiviral activity against RNA viruses [327, 380]. 
However, it is not known how RNA binding of RIG-I triggers TRIM25 activation.  
Mouse TRIM30, the closest relative to TRIM5α proteins of other species, is able to bind 
to transforming growth factor-β-activated kinase 1 (TAK1) thereby initiating the 
degradation of TAK-1-binding protein 2 (TAB2) and TAB3, two proteins that are 
responsible for the activation of Iκ-B kinase (IKK) after Toll-like receptor (TLR) 
signalling, ultimately resulting in the inhibition of NF-κB activity [335]. In this way 
TRIM30 presumably regulates TLR signalling and inflammation. Similarly, human 
TRIM27 has the ability to bind to IKKs and thereby negatively regulates NF-κB and 
interferon response factor 3 (IRF3) activity [336].  
In addition to the regulation of interferon and cytokine production by regulating 
pathogen recognition pathways TRIM proteins can also influence type-I and type-II IFN 
induced signalling pathways. IFN induced signalling pathways need to be tightly 
regulated to avoid uncontrolled inflammation. The suppressor of cytokine signalling 1 
(SOCS-1) inhibits nuclear translocation of signal transducer and activator of 
transcription 1 (STAT-1) homodimers, which mediate IFN-γ signalling, and is itself 
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under negative regulation by TRIM8 [375]. Both, TRIM8 and SOCS-1 expression are 
stimulated by IFN-γ suggesting a mechanism for fine tuning of the IFN induced 
response.   
TRIM21 may also be involved in responses to infections due to its ability to 
ubiquitinate IRF8, leading to an enhanced activity of this transcription factor and an 
increased cytokine production [381]. Indeed, when overexpressed in CD28-stimulated 
Jurkat T-cells, TRIM21 increases interleukin 2 (IL-2) production, and RNAi mediated 
reduction of TRIM21 reduces IL-2 synthesis [382]. TRIM21 was also shown to 
ubiquitinate IRF3 leading to its degradation and therefore could be regulating not only 
the interferon response, but also the production of IFN-α and IFN-β after pathogen 
recognition [329]. Intriguingly, TRIM21 has been shown to act as an Fc receptor 
binding IgG via its PRY-SPRY domain [383]. This suggests that it may recognise 
opsonised viruses or bacteria and may mediate the initiation of an antiviral response via 
activation of IRF8, but this has yet to be tested.  
In addition to effects on the innate immune system several TRIM proteins have been 
connected to a variety of human diseases often associated with point mutations or the 
generation of aberrant fusion proteins. Mutations in the PRY-SPRY domain of TRIM20 
(pyrin) for example, are the cause of the disease Familial Mediterranean Fever (FMF) 
[384]. Mutations in the B-box domain of MID1 (TRIM18) are associated with X-linked 
Opitz G/ BBB syndrome [385] and a mutated form of TRIM32 is found in limb-girdle 
muscular dystrophy [386]. In some cancers the TRIM27-RET fusion protein acts as an 
oncogene [387, 388] whereas in cases of acute myeloid leukaemia (AML) TRIM19 is 
fused to the retinoic acid receptor (RAR) creating a potent oncogene [389]. Other TRIM 
family members have been associated with autoimmune disorders. In systemic lupus 
erythematosus (SLE) and Sjögrens syndrome TRIM21 and TRIM68 represent the Ro52 
and SS-56 auto-antigens, respectively [390, 391]. In Sjögrens syndrome the antigenic 
epitopes that are targeted are found in the TRIM21 coiled coil region and the region 
between the RING and the B-box domain [392]. Direct involvement of many TRIM 
proteins in controlling virus replication but also the indirect role of TRIM family 
members on virus propagation by regulating pathogen recognition, and IFN induced 
signalling pathways highlight the important role this protein family has in innate 
immunity against viral infections.   
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1.9. The role of cyclophilins in HIV-1 biology 
1.9.1. Cyclophilins are widely expressed PPIases with conserved functions 
Cyclophilins (Cyps) are small molecules with an enzymatic activity that enables them to 
change the isomeric state of peptide bonds at proline residues between cis and trans. 
Along with two other protein families, the FK506-binding proteins (FKBP), the 
parvulins and the recently identified Ser/Thr phosphatase 2A activator (PTPA), 
cyclophilins are assigned to the group of peptidyl- prolyl- cis- trans- isomerase enzymes 
(PPIases). FKBPs and Cyps are sometimes referred to as immunophilins because they 
can suppress immune responses in a complex with the drugs FK506 or cyclosporine A 
(CsA), respectively. The PPIase activity of cyclophilins was first demonstrated in 1989 
[393]. The enzymatic function of PPIases has been implicated in protein folding of 
diverse proteins including ribonuclease T1 and collagen [394, 395]. It is believed that 
PPIases in general accelerate protein folding thereby supporting correct and efficient 
function of the target protein. In addition, changes in the secondary structure of proteins 
by isomerisation of peptide bonds may serve as a timed trigger and therefore may be 
seen as a molecular mechanism to time specific events. The first cyclophilin was 
discovered in 1984 by affinity purification using a CsA column [396]. PPIase proteins 
are found in all eukaryotes, prokaryotes and archea and therefore represent an 
evolutionary conserved repertoire of proteins for diverse functions. Recently, the first 
virally encoded cyclophilin was described in the Mimivirus but its function remains to 
be discovered [397]. 
Cyclophilins are widely expressed and are highly conserved between species [398, 399]. 
This suggests that they have evolved to perform conserved functions. This is in contrast 
to the FKBPs PPIases, which differ substantially in their sequences between different 
species and may have evolved to perform species-specific functions [399]. Humans 
express at least 17 Cyps including proteins containing cyclophilin like domains, e.g. the 
nuclear pore protein Nup358, also called RanBP2 or Cyp358. Cyps differ substantially 
in their sizes ranging from 18kDa for CypA to 358kDa for Nup358. The subcellular 
localisations of cyclophilins are also very diverse. Human CypA is found in the 
cytoplasm and the nucleus, CypB is associated with the endoplasmic reticulum, CypC is 
mainly cytoplasmic, CypD is found in mitochondria, CypE is localised in the 
cytoplasm, Nup358 is present at nuclear pores and human Cyp19 is localised at the 
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nuclear spliceosome [399]. Some cyclophilins have N- or C-terminal accessory domains 
of diverse functions (e.g. the heat shock protein associated cyclophilin Cyp40 possesses 
three tetratrico peptide repeat (TPR) motifs C-terminal of its Cyp domain; the 
cytoplasmic cyclophilin CypE has got a RNA binding domain N-terminal of its Cyp 
domain). It is possible that the function of these domains is to recruit target molecules 
for enzymatic catalysis by the attached PPIase domain. However, in case of TRIMCyp, 
a natural occurring fusion protein between CypA and TRIM5, the CypA domain binds 
to the virus capsid and functions as the recruiting domain, whereas TRIM5 mediates the 
recruitment of the proteasome (see 1.9.4.).  
Cyclophilin A (CypA), formerly referred to as cyclophilin 18 (Cyp18), is an important 
and probably the most studied member of the cyclophilin family and has been shown to 
perform diverse roles in numerous biological processes. However, CypA knockout does 
not impact on the viability of mice or cells, suggesting that functions in the cyclophilin 
family may be redundant [400, 401]. CypA was demonstrated to modulate signalling of 
the interleukin-2-tyrosine kinase (Itk). More precisely, CypA mediates a conformational 
switch in the SH2 domain of Itk resulting in the inhibition of signalling and the increase 
of PLCgamma1, a downstream substrate of Itk. The role of CypA to switch the 
conformation and function as a molecular timer has also been proposed for other 
PPIases and is depicted in FIG 25 [402].  
Several cellular interaction partners have been found for CypA. A yeast-two hybrid 
screen identified the transcription factor YY1 as an interaction partner, suggesting that 
CypA may also be able to modulate transcription [403]. Retinoblastoma (Rb) protein 
was also found to interact with CypA and was proposed to interfere with signalling in 
T-cells [404]. In addition to the direct effect, CypA may also regulate pathways 
indirectly. Some studies suggest that cellular and virion associated CypA may mediate 
signalling events in HIV-1 infected cells by binding to different receptors (e.g. CD147 
and CXCR-4), however the effects and implications on the virus life cycle remain 
poorly characterised and understood [405-407]. Furthermore, overexpression of CypA 
has been observed in different cancers, especially in solid tumours, and has been 
proposed to confer resistance to hypoxia induced apoptosis, suggesting that perturbing 
CypA expression levels may contribute to tumorigenesis [408]. Despite many suggested 
interaction partners, it is not clear how many proteins are isomerised by CypA. 
However, the consensus sequence FGPXL has been suggested as a binding and 
isomerisation site and is found in many cellular proteins [409]. The HIV-1 CypA 
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binding site in CA however has the sequence AGPIA, suggesting some flexibility in the 
CypA binding motif. 
Potentially, due to its multiple cellular interaction partners, CypA has been described as 
being involved in the life cycles of diverse viruses, including vaccinia virus, vesicular 
stomatitis virus, mouse cytomegalovirus, hepatitis C virus and influenza virus [410-
414]. The effects of CypA on virus replication differ. In some cases CypA acts as a 
cofactor and stimulates virus replication as seen for example human CypA activity on 
HCV and HIV-1 replication [400, 412]. In other cases, CypA acts as an inhibitor for 
virus replication, as seen for example for human CypA activity on influenza A [411]. In 
contrast to retroviral restriction factors like TRIM5α or APOBEC3G, CypA shows a 
surprisingly low ratio of non-synonymous to synonymous substitutions per site when 
human and non-human primate CypA sequences are compared, suggesting that it has 
not been under positive selection during evolution but rather has been under purifying 
selection [398].  
 
  
 
FIG 25 Prolyl-cis-trans-isomerase reaction mediated by cyclophilins and FKBP proteins  
Depending on the isomeric state of the proline targeted for isomerisation by Cyps or FKBPs, the protein 
or domain can exert different functions. In case of TRIM5α restriction, CypA functions as an auxiliary 
protein. It is possible that different sensitivities for TRIM5α binding can be related to the isomeric state of 
the targeted proline. Figure adapted from [402].  
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1.9.2. The PPIase activity of cyclophilins  
Cyclophilins and FKBPs perform their enzymatic activity as monomers [415, 416]. The 
catalytic function of PPIases is to lower the activation barrier and/ or to raise the energy 
of the bound substrate to the energy of the transition state, in the case of PPIases the 90-
syn state in which the N-terminal peptide chain is rotated at 90˚ compared to the cis or 
trans state. Several mechanisms of how this is accomplished by the enzyme have been 
proposed, however the exact mechanism is still unknown [402]. One hypothesis is that 
to interact with the active site of PPIases the substrate is desolvated and liberated from 
polar interaction partners decreasing the torsion barrier. In addition, intramolecular 
interactions in the substrate may contribute to lowering the transition barrier. Another 
theory is that PPIases bind preferentially to the 90-syn state and interact less efficiently 
with the cis or trans state. In any case, PPIases are able to perform reactions in both 
directions from cis to trans and from trans to cis, however since the free energy of the 
cis state is higher than that of the trans state, or in other words the activation barrier for 
the trans to cis reaction is higher, reactions from trans to cis need more energy 
suggesting that prolyl-peptide bonds in the trans state are more prevalent in a protein 
than the cis state.  
CypA and other cyclophilins bind to the drug cyclosporine A (CsA) and the structure of 
human CypA bound to CsA has been solved (FIG 26). CsA is a cyclic polypeptide 
consisting of 11 amino acids. It is produced as a metabolite by the fungus Beauveria 
nivea [417]. Chemically, CsA is [R-[R*,R*-(E)]]-cyclic(L-alanyl- D-alanyl- N-methyl- 
L-leucyl- N-methyl- L-leucyl- N-methyl- L-valyl- 3-hydroxy-N,4-di-methyl-L-2-amino-
6-octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-
leucyl). In addition, analogues of CsA are synthesised by the fungus. FKBPs do not 
bind to CsA but are able to bind to tacrolimus (FK506) and rapamycin (sirolimus). 
Binding of the drugs to the PPIase active site inhibits its enzymatic function by steric 
hindrance of substrate binding. CypA consists of eight anti-parallel beta-strands that 
generate a beta-barrel, which is closed by two alpha helices each at one end of the 
barrel. CsA as well as the substrate bind to the outer surface of the barrel as shown in 
FIG 26 and FIG 27. CsA has been widely used as an immunosuppressant and its activity 
is exerted by a CypA-CsA complex that binds to and inhibits Ser/ Thr phosphatase 2B 
(PP2B), also known as calcineurin [418]. FK506 bound to FKBPs functions in a similar 
way, whereas binding of rapamycin to FKBPs leads to the inhibition of the target of 
rapamycin (TOR), a protein involved in diverse processes including cell division and 
